Graduate Theses, Dissertations, and Problem Reports
1999

The relationship of disease severity, health beliefs, and
medication adherence among HIV patients
Xin Gao
West Virginia University

Follow this and additional works at: https://researchrepository.wvu.edu/etd

Recommended Citation
Gao, Xin, "The relationship of disease severity, health beliefs, and medication adherence among HIV
patients" (1999). Graduate Theses, Dissertations, and Problem Reports. 1054.
https://researchrepository.wvu.edu/etd/1054

This Thesis is protected by copyright and/or related rights. It has been brought to you by the The Research
Repository @ WVU with permission from the rights-holder(s). You are free to use this Thesis in any way that is
permitted by the copyright and related rights legislation that applies to your use. For other uses you must obtain
permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license
in the record and/ or on the work itself. This Thesis has been accepted for inclusion in WVU Graduate Theses,
Dissertations, and Problem Reports collection by an authorized administrator of The Research Repository @ WVU.
For more information, please contact researchrepository@mail.wvu.edu.

The Relationship of Disease Severity, Health Beliefs,
and Medication Adherence among HIV Patients

Xin Gao

Thesis Submitted to the School of Pharmacy
at West Virginia University
in partial fulfillment of the requirements
for the degree of

Master of Science
in
Pharmaceutical Systems & Policy

David Nau, Ph.D., Chair
Sidney Rosenbluth, Ph.D., Co-Chair
Virginia Scott, Ph.D.
Carol Woodward, Pharm.D.

Department of Pharmaceutical Systems & Policy

Morgantown, West Virginia
1999

ABSTRACT
THE RELATIONSHIP OF DISEASE SEVERITY, HEALTH BELIEFS,
AND MEDICATION ADHERENCE AMONG HIV PATIENTS

Xin Gao

Purpose. To investigate the relationship of disease severity, health beliefs, and
medication adherence among HIV/AIDS patients.
Results. Seventy-two HIV patients were enrolled. There were no significant differences
in patients’ perceived severity of HIV/AIDS and perceptions of benefits and barriers of the
treatment across three disease stages. However, patients who had greater experience with the
disease (stage C) perceived a higher risk to develop complications if they were not adherent
compared to asymptomatic patients (stage A). Results also revealed that patients in stage B and C
were more adherent to their medications compared to patients in stage A when regimen
complexity was controlled. Finally, perceived susceptibility-inaction was positively related to
medication adherence and difficulty in following doctors’ instructions was negatively related to
adherence.
Implications. Patients' medication taking behaviors can be improved by targeting issues
specific to the individual patient and helping patients understand the negative consequences of
poor adherence.
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CHAPTER 1
INTRODUCTION

Background of Problem
Prevalence of Human Immunodeficiency Virus
Human Immunodeficiency Virus (HIV), the cause of Acquired Immune
Deficiency syndrome (AIDS), now infects more than a million people in the United
States and millions more in other countries (World Health Organization, 1996). HIV is
spread via sexual contact, exposure to contaminated blood or blood products, perinatally,
and through contaminated breast milk.

Once transmitted, the virus infects CD4

lymphocytes, leading to their destruction and immune system compromise. Ultimately,
HIV infection culminates in the clinical manifestations known as AIDS. It encompasses
a complex disease state characterized by progressive immune system dysfunction,
opportunistic infections, and unusual malignancies (Quinn, 1995). Prior to 1994, it was
predicted that 80% of patients with HIV would die from AIDS-complicating
opportunistic infections and malignancies (Lane et al., 1994).

Thus far, more than

300,000 persons have died from AIDS-related illnesses in the United States. Among
those most affected are individuals between 25 to 44 years of age. In 1993, AIDS
became the leading cause of death among this age group (Centers for Disease Control and
Prevention, 1997).
AIDS also poses the greatest threat to public health of any communicable disease
in contemporary times. It is unique in its combination of risk factors: the underlying
disease process cannot currently be prevented or treated; the etiologic viral agent is noted
for its propensity to exhibit phenotypic variability and to mutate easily, making the future
development of vaccines or treatment more difficult; there is no finite incubation period,
so carriers of the virus are chronically infectious; and the major risk groups lack
appropriate and timely health care and are vulnerable to social prejudice and private
discrimination (Michael, 1986).
Overall in the United States, there has been a stabilization in HIV prevalence and
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a slowing in AIDS incidence rates. However, a significant number of individuals (at least
40,000) continue to become infected annually, and among certain subpopulations the
epidemic is growing (Rosenberg, 1995).

The number of AIDS cases has grown

disproportionately for women, African-Americans, and Hispanics. AIDS is becoming
more prevalent in the southern United States, and heterosexual HIV transmission is more
prominent now than ever before (Centers for Disease Control and Prevention, 1996). The
population of HIV patients is becoming diverse. While the disease was initially found
among intravenous drug users, male homosexuals, and hemophiliacs, it has become
increasingly prevalent among men and women of all ages and social orientation.
The effort to reduce the spread of HIV has never stopped. The provision of care
for persons with AIDS or other HIV-related conditions will place an increasing burden on
the health care system of the United States for many years. Decreases in AIDS diagnoses,
coupled with decreases in mortality, mean that an increasing number of people will need
HIV medical care (Institute of Medicine, 1986). HIV/AIDS is increasingly viewed as a
chronic, fatal illness requiring a continuum of preventive, acute, chronic, and palliative
care services (Hanley, 1996). It is believed that if the care of these patients is to be both
comprehensive and cost-effective, it must be conducted as much as possible in the
community, with hospitalization only when necessary (Borfitz, 1994). Furthermore, less
hospitalization enables a chronically ill individual to maintain a sense of autonomy and
dignity in coping with his or her progressive physical deterioration. The current trend is to
develop and promote self management of disease in HIV patients. Thus, patients' ability
to manage their therapy becomes a critical issue.
Stages of HIV/AIDS
Active replication of HIV is the cause of progressive immune system damage in
infected persons. In the absence of effective inhibition of HIV replication by antiretroviral
therapy, nearly all infected persons will "suffer progressive deterioration of immune
function resulting in their susceptibility to opportunistic infections, malignancies,
neurologic diseases, and wasting, ultimately leading to death" (Enger et al., 1996; Haynes
et al., 1996).
For adults in developed countries, the average time to develop AIDS after initial
infection is about 10 to 11 years when only nucleoside analogue monotherapy or no
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therapy is provided (Enger et al., 1996). Some individuals develop AIDS within 5 years
of infection (~20%), whereas others (<5%) have sustained long-term (>10 years)
asymptomatic HIV infection without decline of CD4+ T-cell counts to below 500
cells/mm3. Only about 2 percent or less of HIV-infected persons seem to be able to
contain HIV replication to extremely low levels and maintain stable CD4+ T-cell counts
within the normal range for greater than 12 years (Haynes et al., 1996).
There are various staging systems for HIV disease. Stages of HIV/AIDS can be
loosely described in terms such as early asymptomatic HIV disease, AIDS-related
complex (ARC), and AIDS (Institute of Medicine, 1986).

From 1987 to 1993,

classification of HIV-related disease as AIDS depended upon the presence of one or more
indicator conditions listed by the CDC (Centers for Disease Control and Prevention,
1992).

These conditions, including a number of opportunistic infections, Kaposi’s

sarcoma, several types of lymphoma, HIV encephalopathy, and HIV wasting syndrome
were used as AIDS indicators because they were very rare in the absence of compromised
cell-mediated immunity due to advanced HIV infection. The case definition of AIDS was
expanded on January 1, 1993 by the CDC in order to more accurately reflect the number
of individuals with severe immunosuppression. This more frequently utilized system
involves the assessment of indicator conditions as well as CD4+ lymphocyte count
determinations. Indicator conditions are classified into categories A, B, and C. Category
A includes patients without symptoms or those with persistent

generalized

lymphadenopathy. Category B includes signs or symptoms such as oral candidiasis, oral
hairy leukoplakia, recurrent vaginal candidiasis, fever or diarrhea, and cervical dysplasia.
Category C includes most of the opportunistic diseases associated with advanced HIV
disease.

These include Pneumocystis carinii pneumonia, esophageal candidiasis,

cytomegalovirus disease, etc. CD4 lymphocyte counts are categorized as (1) more than
500 cells/mm3, (2) between 200-500 cells/mm3, and (3) less than 200 cells/mm3.
According to the 1993 CDC classification system for HIV/AIDS, patients who have any
indicator C condition or a CD4 lymphocyte count less than 200 cells/mm3 are considered
to have AIDS (Appendix A & B, Centers for Disease Control and Prevention, 1992). In
current practice, laboratory parameters of plasma HIV RNA (viral load) and CD4+ T cell
count, as well as the clinical conditions (symptomatic or asymptomatic) of the patient, are
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monitored together to identify the stage of HIV/AIDS and determine the corresponding
treatments (Appendix C, Centers for Disease Control and Prevention, 1997).
Pharmacotherapy for HIV/AIDS
The goal of treatment for HIV infection is to maintain immune function in as near
a normal state as possible, prevent disease progression, prolong survival, and preserve
quality of life by effectively suppressing HIV replication.

For these goals to be

accomplished, therapy should be initiated, whenever possible, before significant
irreversible immune system damage has occurred (Centers for Disease Control and
Prevention, 1997). Recent findings regarding high-level viral replication favor early
therapy using combinations of the two FDA-approved classes of medications: reverse
transcriptase inhibitors (nucleoside and non-nucleoside analogues) and protease inhibitors
(Enger, et al., 1996; Gasbrro, 1996). Based on current data, the most potent drug
combination includes two nucleoside analogues and a protease inhibitor, although
protease inhibitors are sometimes reserved for use in patients with high viral loads,
symptomatic disease, or rapidly declining CD4 cell counts (Gulick, et al., 1996).
Five nucleoside reverse transcriptase inhibitors are commercially available:
zidovudine (azidothymidine, AZT, ZDV, Retrovir®, Glaxo Wellcome); didanosine (ddI,
dideoxyinosine, Videx® , Bristol-Myers Squibb); zalcitabine (ddC, dideoxycytidine,
Hivid®, Hoffman-La Roche); stavudine (d4T, Zerit®, Bristol-Myers Squibb); and
lamivudine (3TC, Epivir®, Glaxo Wellcome) (Gasbrro, 1996; Pietroski, 1996).
Nonnucleoside reverse transcriptase inhibitors are highly selective for HIV-1, with little
activity against HIV-2 (Pollard and Onorato, 1995).

Nevirapine (Viramune®,

Boehringer-Ingelheim) and delavirdine mesylate (DLV, Rescriptor®, Pharmacia &
Upjohn) are the only two commercially available nonnucleoside reverse transcriptase
inhibitor (Pietroski, 1996; Pollard and Onorato, 1995). Few protease inhibitors have
progressed to clinical trials because of bioavailability, protein binding, and toxicity
issues. As of the end of 1996, three protease inhibitors were commercially available:
saquinavir (SQV, Invirase®, Hoffman-La Roche); ritonavir (Norvir®, Abbott); indianvir
(Crixivan®, Merck) (Pietroski, 1996; Anonymous, 1996); and Nelfinavir (Viracept®,
Agouron). In 1997, a combination of zidovudine and lamivudine (Combivir®, Glaxo
Wellcome) was introduced (Vogel, 1997).
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Adverse effects associated with reverse transcriptase inhibitors and protease
inhibitors are relatively common. They include nausea, vomiting, headache, liver
dysfunction, rash, peripheral neuropathy, diarrhea, abdominal discomfort, asthenia, and
other problems (Pietroski, 1996; Glaxo Wellcome, 1996; Roxane Laboratories, 1996;
Cohen and Noormohamed, 1996).
Medication Adherence of HIV/AIDS Patients
Patient non-adherence with prescription medications is a very serious issue.
Studies have suggested that many patients do not take their medications as prescribed:
they may modify the regimen themselves, or they may not fill/refill their prescriptions at
all (Gibaldi, 1996; Haynes, et al., 1996; Osman, 1996; Pablos, et al., 1996). Nonadherence is especially common with drugs that do not produce an immediate positive
reinforcement for continuing to take the medications properly, or drugs for which the
side-effect are frequent and severe (Osman, 1996). Many drugs for AIDS do not produce
an immediate, if any, improvement in the way the patient feels. In addition, many
antiretrovirals are very toxic agents, and may cause severe adverse effects. Thus, persons
with AIDS are very likely to modify or discontinue their drug therapy.
Drug regimen complexity is also associated with medication non-adherence
(Bjornson, et al., 1992). Recent studies have shown that patients on monotherapy tend to
develop resistance to the drug in 12 to 15 months’ time, and that a better response is
possible by combining two or more antiretrovirals that act on different points along the
replication cycle of the HIV virus (Borfitz, 1994). Although combination antiretroviral
therapy can reduce HIV viral load to undetectable levels in 80% of patients, patient
adherence may be poorer with increased regimen complexity (Woodward, 1996).
Finally, the common drugs used in the management of AIDS patients are very expensive.
For example, the approximate monthly cost for Saquinavir, Indinavir, Ritonavir, and
Nelfinavir are $590, $502, $677, $557, respectively (Tseng, 1998). Thus, monetary cost
further decreases the likelihood of the patient obtaining and using the medications.
In summary, the perceived effectiveness of medications, adverse effects,
complexity of regimens, and monetary cost of antiretroviral treatment contribute together
to a relatively high non-adherence rate of drug therapy in HIV/AIDS patients.
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Clinical and Economic Impact of Non-adherence in HIV Patients
Patient adherence is essential to the success of drug therapy. Failure to adhere to
therapeutic regimens is recognized as a major obstacle to obtaining effective medical care
(Kaplan and Simon, 1990). The most powerful therapy will provide no benefit if taken
incorrectly, and non-adherence may lead to the aggravation of illness or the emergence of
multidrug-resistant HIV (Pablos, et al., 1996). Adherence is particularly important with
antiretroviral agents. Continuous treatment is required for sustained viral suppression.
Even short interruptions in therapy may result in enhanced HIV replication (Havlir and
Richman, 1996).
While the costs of non-adherence may not always be apparent, they are
substantial. Because of patient non-adherence and its widespread occurrence, health care
costs are increasing (Colley and Lucas, 1993). Patient non-adherence has been identified
as a major public health problem that imposes a considerable financial burden upon
modern health care system (Donovan, 1995). A meta-analysis of relevant studies showed
that approximately 5.3% of hospital admissions were related to medication nonadherence at a cost of more than $8 billion in direct hospitalization costs. When indirect
costs are included, the estimates of total expenditures resulting from non-adherence have
ranged from $25 billion to greater than $100 billion (Sullivan et al., 1990). Another
study shows that pharmacies lose more than $1.5 billion in revenues each year as a result
of patients’ failure to refill prescription medications.

This is especially true of

medications for chronic conditions (Felkey, 1995).
For health insurers in particular, improving patient adherence is one key to
decreasing overall health costs. Non-adherence is costly to health benefit plans because it
may result in additional physician visits, emergency room visits, and hospitalizations. In
brief, patient non-adherence is costly for disease management and patient outcomes.
Because of the recognition that adherence to therapy is ultimately cost-effective, third
party payers are now encouraging and compensating for adherence-related services, such
as medication unit-dose packaging, drug regimen organization and review, starter doses,
patient monitoring for drug effectiveness, and installation of electronic medication
dispensers at home (Felkey, 1995).
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Problem Statement
Patients make critical decisions that affect the therapeutic outcome of their
disease (Donovan and Blake, 1992). In this sense, patients share power with providers in
the consumption process. Patients’ beliefs about disease and medications may be crucial
to their intentional adherence behaviors and may be very different than providers
(Donovan and Blake, 1992). Thus, an apparently irrational act of non-adherence from the
physician’s or pharmacist’s point of view may be a very rational action when seen from
the patient’s perspective. These incongruent perspectives may produce considerable
frustration for patients and health care providers.
Patient’s health beliefs and medication adherence may be affected by the severity
of disease (Spilker, 1992; Graham et al., 1994; Smith, 1996). However, very little is
known about how disease severity affects perceptions of health status, perceived benefits,
and perceived barriers of treatment, and further affects decision-making regarding
medication adherence among HIV/AIDS patients.
Symptoms can vary greatly in frequency and severity among HIV patients. Thus,
there is likely to be considerable variability among HIV patients’ perceptions of disease
severity and progression, perceived benefits and costs of medication adherence, and other
factors. Consequently, providing generalized information about HIV may not improve a
patient’s adherence behaviors. The effectiveness of an education intervention will be
enhanced if the information targets the key perceptions of that patient. The effectiveness
of adherence-gaining strategies may depend upon the extent to which they match
patients’ beliefs about health and medications. Therefore, knowing whether patients’
beliefs about their health and medications change in a predictable way as their disease
progresses may lead to the more effective design of drug therapy regimens and
counseling approaches.

Goal of Study
This study will investigate the relationship of disease severity, health beliefs and
medication taking behaviors among HIV patients.
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Study Objectives
1. Compare the perceived severity of HIV/AIDS among HIV patients in different
disease stages.
2. Compare the perceived susceptibility to AIDS related complications among HIV
patients in different disease stages.
3. Compare the perceived benefits of antiretroviral therapy among HIV patients in
different disease stages.
4. Compare the perceived barriers to medication adherence among HIV patients in
different disease stages.
5. Examine medication adherence of HIV patients with antiretroviral therapy in different
disease stages.
6. Investigate the influence of regimen complexity and health beliefs on self-reported
medication adherence.

Research Significance
To increase the effectiveness and minimize the costs of health care, it is important
to understand patients’ decision-making and the strategies that can enhance patients’
medication adherence. A health care provider who understands a particular client’s
perspective has a tremendous advantage for helping the treatment.

This study

investigated how disease severity affects HIV patients’ health beliefs and medication
adherence. This information could be useful in helping health care providers understand
patient motivations for discontinuing their antiretroviral treatment and helping patients
collaboratively develop treatment regimens that facilitate adherence and optimize the
outcomes of HIV/AIDS therapy. Finally, this study may help clinicians and researchers
predict adherence rates of antiretroviral therapy, and develop well-aimed and effective
interventions enhancing medication adherence in HIV/AIDS patients.
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CHAPTER 2
LITERATURE REVIEW

This chapter summarizes the results of an extensive review of the available
literature regarding treatment adherence. The definition, measurement, and determinants
of treatment adherence are included. The literature about the relationship of disease
severity and treatment adherence among HIV/AIDS patients are also discussed.

Defining Treatment Adherence
Throughout this chapter, the terms "adherence" and "non-adherence" are used and
considered equivalent to the terms compliance and noncompliance. Some have argued
that although compliance and adherence are often used interchangeably (Dunbar et al.,
1989; Sluijs and Knibbe, 1991; Leventhal and Cameron, 1987), important distinctions
exist that reflect assumptions about the nature of patient-prescriber relationship. These
assumptions are especially important in how they shape the expectations and
interchanges between patients and prescribers. Given the nature of patient-prescriber
relationship, the concept of "compliance" implies an obligation to passively obey, yield,
or submit to a request or command from a higher authority (Meichenbaum and Turk,
1987; DiMatteo and DiNicola, 1982; Gerber, 1986). In contrast, the concept "adherence"
does not imply the same passive obligation to obey, nor does it have the implication of
punishment if a person is non-adherent. The activity implied with the concept adherence
is one of voluntary choice in which a commitment is made to closely follow a plan or
one's beliefs (Johnson, 1993).
Compliance has been defined as the extent to which a person’s behavior, in terms
of taking medications, following diets, or making other lifestyle changes, coincides with
medical or health advice (Haynes, 1979). This is a very broad and theoretical definition.
In reality, however, the concept of treatment adherence is far from being clear and
straightforward. Defining adherence to complex medical regimens is especially difficult.
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Complex regimens require many different kinds of medication-taking behaviors, usually
on a daily basis (Johnson, 1993). This is particularly true for persons with HIV infection
who take combinations of antiretroviral medications. Because of differing bioavailability
and half-lives, protease inhibitors may have to be taken at fixed intervals of either 8 or 12
hours around the clock, either with meals (e.g., saquinavir, nelfinavir, or ritonavir) or on
an empty stomach (e.g., indinavir). Such a regimen usually also includes two other
antiviral drugs (e.g., reverse transcriptase inhibitors) that will likely have different
schedules. HIV patients may also be expected to make frequent clinic visits because they
require close monitoring (Muma, 1995). Additionally, restrictions on diet and other
aspects of the daily activities further complicate the treatment regimen.

The sheer

number of treatment-related behaviors makes complete treatment adherence difficult for
persons with HIV.
While the Haynes definition of compliance is widely accepted, it has not escaped
criticism. Johnson (1993) and Rudd (1993) argued that Haynes’ definition of adherence
was based on several assumptions such as proper diagnoses, effective treatment, and clear
instructions. The physician’s medical advice that was used by Haynes’ definition as the
standard to which the patient’s behavior was compared was nonexistent or unclear for
many complex treatment regimens. Thus the standard itself was suspicious according to
Johnson and Rudd. They suggested that defining adherence require some sense of an
ideal standard, clearly documented by the physician or by the investigator. However,
their suggestion makes it almost impossible to define and compare adherence since the
“ideal standard” is highly individualized and changes with time. For most adherence
studies, it seems unnecessary to doubt the accuracy of diagnoses and prescriptions at the
time adherence is defined. Regarding medication adherence, the only standard should be
the prescription and related instructions to the patient.
In this study, treatment adherence was simplified as medication adherence. It
focused only on adherence to the drug regimen rather than a comprehensive assessment
of treatment adherence. Adherence in this study was defined as the extent to which HIV
patients take their medications as prescribed. This definition was more specific and made
the measures of adherence more understandable.
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Measuring Treatment Adherence
Various methods have been developed to measure adherence. These methods are
generally categorized as either direct or indirect measures (Rudd, 1993). Direct measures
include blood or urinary levels of medications, metabolites, or markers.

Indirect

measures include pill counts, prescription refills, self-report, clinicians' opinions, and
medication-event monitoring systems (MEMS).
The direct biologic measures, like biologic assays of active drug or metabolite,
confirm actual drug ingestion. However, assays are not feasible in most ambulatory
settings due to their high cost and inconvenience for patients. Additionally, significant
variance may exist between patients in their absorption, metabolism, and excretion of
medications (Gordis, 1979). There is no clear causal linkage between lab parameters and
adherence behaviors. Hence, assays provide little information about the consistency of
medication taking.
Pill counts have been employed in many drug trials.

This method requires

subjects to return their pill supply at each visit so that the pills may be counted. Several
obstacles interfere with standard pill counts (Rudd, 1993).

These include subjects’

changed behaviors due to concerns about being judged, forgetting to return pill vials,
losing containers, sharing medication with other individuals, and storing medication in
more than one place. The technique of pill counts is also very labor intensive, which
makes this method impractical in most practice settings. Under this method, adherence is
usually calculated as a percent discrepancy score which is the number of pills the patient
had actually consumed divided by the number they should have consumed during a
specified time interval (Finney et al., 1985; Samet et al., 1992; Foulkes et al., 1993;
Putnam et al., 1994). It is calculated using the following formula [(prescribed doses missed doses)  (prescribed doses)]. Adherence may be reported as a continuous variable
(e.g., percentage) or as a dichotomous variable (adherent/non-adherent) in which
adherence is defined as being within + 10% or + 15% of the appropriate number of doses
to be taken (Rudd, 1993).
The prescription refill method uses pharmacy dispensing records to monitor the
prescribed dosing frequency and interval between prescription refills (Rudd, 1993).
Prescription refill rate is a useful source of adherence information in population based
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studies when direct measurement of medication consumption is not feasible. However,
this method may be confounded by patients obtaining refills at more than one pharmacy
or by sharing medications with others.
Clinician’s opinions are highly specific but relatively insensitive to patients’
adherence behaviors (Rudd, 1993). Physicians may be both unaware of the importance
of the relevant behavioral, psychological, and social aspects of care and lack of time,
skills, or motivation to identify or manage these problems. Clinician’s opinions can be
used as references and combined with other measures.
One of the major improvements in assessing adherence rates has been the use of
interview data (Morisky et al., 1986). Patient self-report method uses self-administered
questionnaires or interviewers to obtain a patient’s subjective evaluation of his or her
own treatment adherence behaviors. It is one of the most frequently used methods in
measuring medication adherence. The advantages of this method over other measures
include its feasibility in all care settings, simplicity, and speed (Morisky et al., 1986).
Disadvantages of this method include recall bias and subjectivity. The reliability of the
self-report method may vary with the study variables such as the type or severity of
disease, but frequently demonstrates acceptable validity and reliability (Rudd, 1993).
Green et al. (1975) first described a five-item self-reported scale measuring
medication-taking behavior in outpatients being treated for high blood pressure. Later, a
four-item scale with relatively high reliability was developed by Morisky et al. (1986)
from the original five items: (1) Do you ever forget to take your medicine? (2) Are you
careless at times about taking your medicine? (3) When you feel better do you sometimes
stop taking your medicine? (4) Sometimes if you feel worse when you take the medicine,
do you stop taking it? The theory underlying this measure was that drug errors of
omission could occur in any or all of several ways: forgetting, carelessness, stopping the
drug when feeling better, or starting the drug when feeling worse. By reversing the
wording of four questions about the way patients might experience drug omissions, the
sum of “yes” answers may provide a composite measure of non-adherence.
When using this scale, medication adherence is measured as an ordinal variable
which is the number of “yes” answers. Then a categorical variable is created in order to
assess adherence level: 0 item Yes means a high adherence level; 1 or 2 items Yes means

12

a medium level; and 3 or 4 items Yes indicates a low adherence level. In Morisky et al.’s
study, the scale demonstrated adequate internal consistency ( = 0.61). Each item in the
scale contributed significantly to the overall reliability coefficient, with a decrease in the
alpha level if any single item was deleted. The validity of this scale is reflected by the
relative balance of sensitivity (0.81) and specificity (0.44) of the scale (Gordis, 1996).
The measurement scale developed in this study is simple and straightforward and easily
conducted in clinic settings.
Electronic compliance monitors are a relatively new method (Rudd, 1993). The
“monitor” is a computer chip embedded in the cap of a prescription container. It records
the actual time at which the container was opened and medication was presumably taken.
The monitor stores multiple days worth of data and can provide a time tracing that
becomes the matrix on which the investigator places other observations, measurements,
and potential predictors in search of associations. Hence, the monitors assess medicationtaking events on a dynamic basis. Such electronic compliance monitoring has become
the new “gold standard” for pharmacologic treatment studies and other adherence
measures. Theoretically, the monitors could provide a probe for factors that facilitate,
cue, or inhibit specific occasions of dispensing and presumably consuming medications.
However, it remains possible that a patient might open and close the monitor and not
actually take the medication. Also, this method is too expensive to be applied to large
samples.
For studies within the HIV/AIDS population, the most common methods for
measuring adherence were self-report, biologic assays, and a combination of the two.
Lim examined the use of serum drug levels to assess adherence to study medication in a
clinical trial (Lim, 1992).

Zidovudine adherence was estimated from serum levels.

However, it is unusual to analyze blood samples directly for zidovudine levels in order to
measure zidovudine adherence. Although this direct method is more accurate, the cost of
the test makes it prohibitive. Since a side effect of zidovudine treatment is a massive
elevation of mean corpuscular volume (MCV) of erythrocytes, macrocytosis is the usual
biologic method for assessing long-term adherence (Sande and Volberding, 1990; Samet
et al., 1992; Muma et al., 1995). Broers et al. (1994) combined MCV test and physicians’
estimates to measure drug users’ adherence with zidovudine treatment. Results showed
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that the physicians’ estimates’ of their patients’ adherence correlated well with MCV
values.

However, both clinicians’ opinions and MCV tests are highly specific but

relatively insensitive to the adherence information (Sande and Volberding, 1990; Samet
et al., 1992; Muma et al., 1995).
Several studies have shown that the self-reports may also be reliable and valid
methods of assessing HIV medication adherence (O’Connor, et al., 1992; Samet et al.,
1992; Geletko, et al., 1995; Muma, et al., 1995). In the study conducted by O’Connor,
medication adherence was measured by documentation that medication was dispensed
monthly and patients’ report that it was taken. In Geletko's study, patients' self-reports
regarding their medication use were verified with the medical records.
In another study of zidovudine adherence among HIV patients, patients’ selfreport verified by MCV method was used (Muma et al., 1995). Adherents were defined
to include those who took zidovudine as prescribed and whose MCV of erythrocytes had
to be more than 100 fl, which is the case when zidovudine is consistently taken. Graham
et al. (1994) reported that when using rise in MCV as the gold standard, validity of selfreports for zidovudine use is high (sensitivity = 88%, specificity = 91%). They then
expanded this conclusion to the self-report method for other related drugs as a proof of
study validity.
Berod et al. applied prescription refill method to measure outpatient adherence
with zidovudine therapy in a community-based study (Berod and Simon, 1993). Since
their pharmacy department was the only pharmacy in French Polynesia that dispenses
zidovudine for outpatients infected with HIV, the problem of multiple-pharmacy
prescription refills did not exist. This is a good example for choosing an appropriate
measurement based on the nature of the study (community-based) and the actual local
condition.
In summary, no measure of adherence proves perfect. The advantages of cost,
convenience, and acceptability have generally served as counterweights to accuracy, nonreactivity, and comprehensiveness. There are critical challenges in research related to
adherence measurement. It has not been possible to find an absolute “gold standard”
measurement that can be applied to all kinds of related research. Choosing the most
appropriate method of adherence measurement will depend on a good understanding of

14

the nature of study and the practical implications of each technique.

Determinants of Treatment Adherence
Treatment adherence is a complex human behavior that is influenced by a variety
of factors. Much research has been conducted in efforts to identify the factors that
influence treatment adherence and methods of improving adherence behavior. Through
1984, approximately 700 studies had been conducted, using more than 200 variables to
assess the determinants of adherence behavior (Morisky et al., 1986). Various sources
report that approximately 25 - 60% of patients do not adhere to their prescribed
medication regimens, especially when life style changes are required as with HIV
medications (Becker & Maiman, 1980; Friedman & DiMatteo, 1989; Muma et al., 1995).
Documented explanations for a lack of adherence with therapeutic regimens in general
have included disease factors, patient personality characteristics, environmental and
situational barriers, complex medical regimens, patients’ health beliefs, and an
inadequate clinician-patient relationship (Rudd et al., 1979; Haynes, 1979; DiMatteo &
Friedman, 1982).
To date, there is limited research that describes the dimensions associated with
HIV medication adherence. Most research has focused on zidovudine adherence (Berod
and Simon, 1993; Broers et al., 1994; Muma et al., 1995; Geletko et al., 1995; Lim,
1992).

Meanwhile, some studies examined medication adherence in HIV positive

intravenous drug users (IVDUs) due to the fact that IVDUs often have significant
medical problems and are in need of comprehensive primary care in addition to drug
treatment (O’Connor et al., 1992). Since few studies have investigated the issue of HIV
medication adherence, a small number of dimensions have been identified to explain
adherence. The study by Samet et al. (1992) identified that adherence was associated
with a diagnosis of AIDS or ARC, the number of medications taken with zidovudine, and
the belief that zidovudine could prolong life. Other reasons proposed by clinicians and
patients to explain zidovudine non-adherence include the high cost of antiretroviral
medication, toxicity associated with the drug, patients’ beliefs about their disease and
medications, misleading information from the media, and minimal or incorrect education
on taking the medication (Baker & Muma, 1991). Broers’s (1994) study also identified
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substance abuse, unstable housing, and concurrent psychiatric problems as contributors to
non-adherence. Disease severity was also reported to affect treatment adherence and
patient perceptions (Smith, 1996; Spilker, 1992).
Morris and Schulz (1993) conducted a comprehensive review on the determinants
of treatment adherence from the patients’ perspective. They recognized that patients
evaluate medication based not only on its clinical effectiveness, but also on how it affects
all aspects of their lives. Four determinants of non-adherence were summarized in their
study: physical, economic, social or interpersonal, and psychological determinants.
Physical Determinants of Non-adherence
Physical experiences with a disease or medications can alter a patient’s pattern of
medication taking. For example, a qualitative study of illness experiences found that
symptom control significantly influenced the adherence to treatment guidelines (Hunt et
al., 1989). Morris and Schulz (1993) showed how physical responses to treatment affect
medication taking. They found that an expected response to treatment, such as a decrease
in pain, may actually improve adherence.

Alternatively, negative experiences with

medications, can result in non-adherence. In the studies they reviewed, non-adherence
from the patient’s perspective was intentional and rational.

Patients evaluated the

effectiveness of the medication to help them decide what medication to take and when.
Patients may alter their medication regimen to control symptoms or avoid side effects in
an attempt to improve their quality of life. Thus, physical responses may influence
medication taking behaviors.
Economic Determinants of Non-adherence
The rising costs of medical care may be an important explanation of nonadherence. Boza et al (1987) reported that financial problems might be a major cause of
noncompliance in elderly and poor patients. In Chubon’s study (1989), many patients
expressed concern about the cost of medications and medical care. Some of them were
forced to go without medications until they had acquired the money to purchase. Fear of
the monetary expense or loss (such as absence from work due to required clinic visit)
associated with obtaining medical care may be inversely associated with adherence.
However, the effect of cost and medical insurance on compliance is inconsistent (Cooper
et al., 1982; Morris and Schulz, 1993). In the study by Cooper et al. (1982), only 6% of
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the elderly respondents reported that a medication was not available or that they could not
afford it.
The inconsistency in the effect of cost on adherence in the literature may be due
to the various populations and type of medicine studied. Variations in insurance policies
and state Medicaid programs such as prescription limits, may also influence the price
sensitivity of medications. People may value medications differently depending on the
condition being treated (Morris and Schulz, 1993).
For HIV/AIDS patients, the common drugs such as ZDV and SQV are very
expensive. On the other hand, the monetary cost may not be a very important issue for
some patients since HIV infection is a life-threatening disease (Samet et al., 1992).
Medication price sensitivity may change with disease severity and the amount of out-ofpocket payment. The influence of monetary cost on medication adherence remains
unclear for HIV population.
Social/Interpersonal Determinants of Non-aherence
Three dimensions can be summarized from the many social factors employed in
adherence-related studies: patient-practitioner relationship, social influence, and
demographic factors.
The effects of patient-practitioner relationship on adherence behaviors have been
studied by many researchers for a long time. Coe and Wessen (1965) have suggested that
numerous aspects of the physician-patient interaction, such as impersonality and brevity
of encounter, negatively influence patient behavior. Stimson (1974) has suggested that a
physician's actions may affect how some people view medications. Most people have
some expectations or beliefs about their treatment such as the expected type, cost, and
amount of medication needed to produce a desired outcome. Treatment adherence of
patients is associated with how well these expectations can be satisfied.

Lack of

communication (both cognitive and emotional) is usually held to be the problem (Becker
and Maiman, 1975; Donovan and Blake, 1992; Remien, 1998). If it is difficult for
patients to understand their treatment or follow the instructions, it may cause
misunderstanding and inappropriate expectations. In a study conducted by Stall et al.
(1996) among gay/bisexual men with HIV, patients who trusted their physicians were
more likely to follow the standard of care guidelines for HIV. Another study by Morse et
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al. (1991) indicated that patients who saw their nurses as supportive were more adherent
to their medication.
Remien (1998) also pointed out that the relationship between patients and other
medical persons is very important. Pharmacists play an essential role in helping patients
understand their treatment regimen and the potential negative consequences of poor
adherence, cooperating with physicians to simplify treatment regimens, and providing
practical suggestions to help patients remember to take all doses of medications.
In addition, studies have shown that several social factors, such as friends and
family members' suggestion or behaviors (Stall et al., 1996; Foulkes, 1993), living alone
(Besch et al., 1997; Morse et al., 1991), having an unstable social environment (Morse et
al., 1991), caring for sick relatives (Muma et al., 1995), and being homeless (Samet et al.,
1992) were associated with lower adherence. Conversely, a good relationship coupled
with consistent support, particularly from a spouse or significant other (Evans et al.,
1986; Somer and Tucker, 1988; Erdman et al., 1993), was associated with better
adherence.
Treatment adherence is also associated with extremes of age (very young patients
or geriatric patients) (Becker and Maiman, 1975).

In general, studies show that

adherence is not consistently related to gender, intelligence, education, or marital status
(Becker and Maiman, 1975). For the HIV population, one study found ethnicity (black
race, independent of drug use or education) (Muma et al., 1995) associated with nonadherence, but three others did not (Eldred et al., 1997; Besch et al., 1997; Morse et al.,
1991). In addition, gender and age may not be related to treatment adherence in the HIV
population (Remien, 1998).
Psychological Determinants of Non-adherence
Health researchers have long attempted to understand the psychological factors
that influence treatment adherence behaviors and relevant decisions.

A number of

belief-based theoretical models have been developed as a way to understand and explain
health related behaviors.

These include the Andersen Behavioral Model (ABM:

Andersen and Newman, 1973; Andersen, 1995); the models rooted in the Subjective
Expected Utility theory (SEU: Edwards, 1954) such as the Theory of Reasoned Action
(TRA: Fishbein and Ajzen, 1975; Ajzen and Fishbein, 1980) and the Theory of Planned
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Behavior (TPB: Ajzen, 1985); the Health Belief Model (HBM: Rosenstock, 1966; Becker
and Rosenstock, 1987); and recent revisions of the HBM (Ronis, 1992; Nau, 1997).
These theories and models have made tremendous contributions to understanding health
behaviors although none are perfect predictors of health behavior.
The Andersen Behavioral Model incorporates sociodemographic, economic, and
social psychological variables in order to explain the use of health services (Andersen
and Newman, 1973; Andersen, 1995).

These variables are conceptualized as

predisposing, enabling, or need factors for the use of health services. Predisposing
factors include immutable demographic variables and the health beliefs that are
embedded in a person’s attitudes, values, and knowledge. Enabling factors include
access,

availability,

and

acceptability.

Need

factors

include

health

status,

symptomatology, or perceived health status. The purpose of this model is to discover
conditions that either facilitate or impede utilization of medical care. It is a very broad
measure of access to medical care. Consequently, it has been employed often to study
the use of health services in general due to the comprehensive nature of its variable set.
The Theory of Reasoned Action (TRA) has been widely used by socio-behavioral
researchers. The Theory of Planned Behavior (TPB: Ajzen, 1985) is an extension of
TRA which has also been called the Behavioral Intention Model (TRA and BIM:
Fishbein 1967; Fishbein and Ajzen 1975). The TRA and TPB postulate that the most
immediate determinant of a person’s behavior is a behavioral intention. Influencing
behavior is achieved through influencing one’s intentions. The TRA models behavioral
intention as a function of two sets of variables, whereas the TPB models intention as a
function of three sets of variables. The two common variable sets are “attitude” and
“subjective norm”. The attitudinal component is taken to be a function of a person’s
beliefs about the outcome of the behavior. Attitudes are conceptualized as being
composed of personal evaluations of each outcome (i) of the behavior multiplied by the
strength of a belief about this outcome (eibi). The sum of these multiplicative
components is then held to be an indirect measure of the attitude towards the behavior.
The subjective norm refers to a summary statement of normative social influences. It is
conceptualized as the sum of products of normative beliefs attributed to each significant
referent person (j) and the motivation to comply with these expectations (nbjmj). There
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is no difference between the TPB and TRA in the first two components. However, the
TPB adds a third determinant called perceived behavioral control.
Perceived behavioral control is the degree to which people perceive themselves to
control their behavior. This additional component takes non-volitional behaviors into
account. It is based on an evaluation of the power of factors likely to facilitate or inhibit
the behavior/action weighted by their frequency of occurrence. Both internal control
factors, such as information and personal abilities, and external control factors, such as
opportunities and barriers, are included in this determinant.
TRA and TPB appear to be extensions of Edwards’ Subjective Expected Utility
theory (van der Plight, 1994). The SEU theory is a mathematical model of decision
making in which people compare the expected utility (desirability) of alternative
behaviors and choose the action with the highest SEU. The SEU of a behavior is the
perceived probability of a specific outcome or consequence of the behavior multiplied by
the desirability of that outcome. The mathematical expression is:
SEUj =  Pij Uij
i

where SEUj is the subjective expected utility of

behavior

j, Pij is the perceived

probability of outcome i of behavior j, and Uij is the subjective utility or desirability of
each possible outcome i of behavior j. Once behavioral alternatives and the relevant
beliefs have been identified, researchers can make specific predictions about the behavior
and the decision making process based on the SEU model.
Past research on TRA, TPB, and SEU has found them quite useful in predicting
behavioral intentions. However, various limitations of these theories have also been
identified (Leventhal and Cameron, 1987; Ronis, 1992). These theories do not provide
clear explanations and predictions on actual behaviors. They do not specify which
outcomes or beliefs are most relevant to a given decision and further to a behavior.
Additionally, it is not easy to apply these theories in health fields. Variables such as the
norms regarding the acceptability of performing the action, the motivation to comply
with these norms, and the probabilities for all outcomes are difficult to define completely
and measure validly in predicting a health-related behavior. People may use simpler
decision rules than those espoused by involved in these theories (Nau, 1997).
The most widely used rational belief theory for explaining health behaviors is the
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Health Belief Model (HBM) which was first introduced by Rosenstock (1966). It has
been frequently used as the major theoretical or organizing framework for explaining and
predicting adherence to health and medical care recommendations (Janz and Becker,
1984; Morse et al., 1991; Geletko et al., 1995; Muma et al., 1995). Unlike ABM, SEU,
TPB and TRA, it is a psychological theory originally aimed at health-related behaviors.
Briefly stated, the HBM is composed of four basic belief dimensions: (1) Perceived
probability of a threat, or the subjective perception of vulnerability to a particular health
condition; (2) Perceived severity of the threat, which includes evaluations of both health
and social consequences; (3) Perceived benefits, or the feasibility and efficacy of the
particular health behavior; and (4) Perceived barriers, or impediments to undertaking the
behavior. The Health Belief Model posits that patients’ perceptions of susceptibility to
and severity of a given disease, as well as perceived benefits and barriers to a particular
treatment or procedure, are predictive of patient adherence to a therapeutic regimen. A
person’s tendency to take an action is hypothesized to be increased by high susceptibility,
high severity, high benefit, and low barriers. HBM also recognizes various “cues to
action”, which include mass media, interpersonal communications, and other stimuli.
Additionally, the value one places on health (Lau et al., 1986), self-efficacy (Bandura,
1977) and health locus of control (Wallston and Wallston, 1981) have been included in
derivations of the model.
The HBM has provided a useful framework for understanding preventive health
behaviors, such as skin cancer protective behavior (Carmel et al., 1994), breast selfexamination behavior (Ronis and Kaiser, 1989), dental flossing behavior (Ronis, 1992),
participation in health screenings (e.g., Ronis and Harel, 1989; Aiken et al., 1994;
Blalock et al, 1990), and immunizations (Becker and Maiman, 1975). The HBM has also
been used in predicting sick-role behaviors which are actions taken to restore good health
or prevent disease progression, such as the compliance to health recommendations and
therapeutic regimens (e.g., Becker, 1974; Becker and Maiman, 1975; Janz and Becker,
1984; Morse, et al., 1991; Geletko, et al., 1995; Muma, et al., 1995). Many investigators
have found it to provide demonstrable explanatory and predictive values. However,
several limitations of HBM exist and should not be ignored. In the HBM, evaluations of
the outcomes/consequences of the behavior are not explicitly represented and, as a result,
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may not be measured. Furthermore, the model does not clearly state the relations among
the four heath beliefs or the relative importance of each belief in the decision making
process. Similarly, the relationship between health beliefs and the various cues of action
such as disease severity has not been stated clearly. Finally, the perceived susceptibility
and perceived severity (the combination of these two variables has also been referred to
as perceived threat in some studies), whether used independently, or with other health
belief variables, have consistently been shown to be less than ideal predictors of a
behavior (Conner and Norman, 1994).
The deficiencies of HBM have led some researchers to revise HBM. Ronis
suggests that the HBM be combined with SEU theory (Ronis and Harel, 1989; Ronis,
1992). In this combined model, perceived susceptibility is equated with the perceived
probability of an outcome (Pij) and perceived severity is equated with the (dis)utility
associated with that outcome (Uij). Thus, according to the SEU theory, the expected
utility of taking an action is linked to the concepts of perceived severity and perceived
susceptibility. At the same time, Ronis suggested that the concept of benefits include all
anticipated desirable consequences of an action and the concept of costs include all
anticipated undesirable consequences of an action. It is very important that in the
integrated model, all perceptions of severity, susceptibility, benefits and costs are defined
by comparison to inaction or other behaviors. Thus, the criterion of decision making is
quantified by the value change of SEU and the behavioral alternative with the highest
SEU is enacted. This is reflected in the mathematical expression: SEU = PijUij , and
more specifically, SEU = ( PijUij )benefits + ( PijUij )costs . The benefits will include
all outcomes/consequences with positive PiUi value and similarly, the costs will include
all outcomes/consequences with negative PiUi value. Note that, due to the multiplicative
combination rule in this SEU formula, a reduction in severity (Ui > 0) produces
perceived benefit only if people believe they are susceptible to the disease (Pi  0).
Ronis also suggests that the concepts of susceptibility and severity need to be
refined in this combined model. They need to be made conditional on the alternative
actions or inaction. For example, it is critically important to distinguish between (a)
susceptibility to a disease/disease progression when an action (preventive action or
adherence to the regimen) is taken and (b) susceptibility to a disease/disease progression
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when the action is not taken. Therefore, perceived susceptibility and severity should be
evaluated in a given condition in which the action (e.g., adhering to the treatment) will or
will not be taken. High susceptibility given inaction is associated with higher possibility
of taking the action and high susceptibility given action is associated with lower
possibility of taking the action. Similarly, high perceived severity given inaction is
associated with higher possibility of taking the action and high severity given action is
associated with lower possibility of taking the action (Ronis, 1992).
The revised HBM was well supported by the studies of breast cancer screening
behavior (Ronis and Harel, 1989), breast self-examination behavior (Ronis and Kaiser,
1989), and dental flossing behavior (Ronis, 1992). However, the failure to find the
interactive influence of perceived severity and perceived susceptibility on perceived
benefits in these studies impairs the reliability of the multiplicative combination of
perceived severity and perceived susceptibility.
The implication of Ronis’ work is obvious. He found that conditional perceptions
of susceptibility and severity were related to the perceived benefits of the behavior and
the behavioral intentions. This is consistent with the suggestion of the TRA (Ajzen and
Fishbein, 1980) that measurements of their behavioral beliefs and behaviors should
correspond closely in terms of the specific action, context, time, and target. The failure to
use conditional measurements may explain the previous inconsistent findings for
perceived severity and perceived susceptibility.
Another modification suggested by Nau (1997) is combining the perceived
susceptibility and perceived severity to form a global perception of the “health threat”
under a consideration that people may not form truly independent perceptions of
susceptibility and severity when evaluating a health problem. This conception has also
been supported by other researchers (Janz and Becker, 1984; Schwarzer, 1992; van der
Plight, 1994). Nau (1997) also suggests that the concept of perceived threat should be
measured as conditional upon engaging in the specified behavior. This should enhance
the specificity of the measured belief. The concept of “perceived benefit” he used is
based on a potential need for the action (e.g., taking a medication or using a health
service). Thus, any reduction in health threats will produce perceived benefit by
reflecting a satisfied need. Then the costs and benefits of taking an action are weighed to

23

determine the value of that behavior. Action is postulated on the balance between benefits
and costs, in which the balance is conceptualized as “perceived value” (Dodds and
Monroe,1985; Wood and Scheer, 1996).
In a study of the use of pharmaceutical care services, Nau (1997) pointed out that
different diseases may produce more variability in perceptions of severity. For example,
Breast cancer is likely to be perceived as severe by nearly all women and gingivitis is
likely to be perceived as mild by most persons. On the contrary, people with HIV
infection or asthma have various symptoms, which could increase the variability in their
perceived severity. Thus, Nau suggested that the lack of variability in persons’
perceptions of the severity of a particular health problem may be an explanation of why
perceived severity (or perceived threat) has played a weak role in predicting certain
health behaviors.
Nau (1997) also suggested that perceived benefits reflect the individual's
assessment of the extent to which engaging in the preventive behavior will produce a
desired health benefit. This health benefit could be a reduction in the likelihood of
developing a health problem. Hence, the extent to which one believes that taking an HIV
medication will reduce his/her likelihood of developing HIV-related problems could be
the basis for the perceived benefit of the HIV medication.
Morris and Schulz used the self-regulation theory developed by Conrad (1985)
and Hunt et al. (1989) to understand psychological aspects of non-adherence. Selfregulation theory suggests that behaviors such as medication non-adherence are likely
influenced by varying multiple factors (e.g., psychological, social, family, and
physiological factors), and thus require self-regulation or self-control for adherence under
the varying conditions that these factors create. Self-regulation theory asserts that
execution of a target behavior (i.e., taking of medication properly) requires (1) being
motivated to do the behavior by internal and/or environmental stimuli, (2) perceiving that
one has control over the behavior, and (3) perceiving support of one’s efforts to do the
behavior. In fact, there are many overlaps between self-regulation and components of
some other theories (e.g., cues to action from Health Belief Model and perceived
behavioral control from Theory of Planned Behavior).
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Disease Severity and Treatment Adherence
As mentioned before, studies have shown that medication taking behaviors are
related to the severity of disease (Spilker, 1992; Graham et al., 1994; Smith, 1996).
Patients with different symptoms of disease and/or patients with different diseases (fatal
or mild chronic) may have different responses to treatment. Disease severity is also
shown to influence health beliefs and typically treated as a cue to action in most studies
using HBM (Geletko, etc., 1995; Conner and Norman, 1994). However, the relationship
between disease severity and other belief factors in HBM is not clear. The relative
importance of disease severity in the model has also not been well studied. Cues to
action (such as media messages and sociodemographic factors) are generally considered
to be outside the model and only influence behavior via their effects on beliefs (Liska,
1984).
Most of the medication adherence literature focuses on illnesses that tend to be
chronic in nature and not immediately life threatening, such as hypertension, heart
disease, and diabetes mellitus (Morse, et al., 1991). HIV infection is a more serious
illness, although recently there have been some medications developed to prolong and
increase the quality of life.
Another aspect of the HIV infection, is that symptoms can vary greatly in
frequency and severity among HIV patients. In the early stages of the disease, for
example, there may be no symptoms experienced by the patient and the consequences of
terminating treatment are delayed (Griffith, 1990). Hence, some patients in this stage may
be more sensitive to the side effects of the medication despite its benefits and may not
feel any discomfort soon after discontinuing their medications.
Due to the nature of the disease and the limited number of studies in this area, it is
difficult to find research covering patients in all different stages of HIV infection. Morse
et al. (1991) conducted a study on determinants of compliance of ZDV for asymptomatic
HIV-infected patients. They found more adherent subjects lived further from their
treatment site, did not live alone, saw their study nurse as supportive, and were more
likely to depend on a significant other for a wide range of social, economic, and
emotional support. On the contrary, Geletko et al. (1995) studied the reasons for
discontinuation of ZDV therapy among patients only with AIDS or AIDS-related
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complex (ARC). Results indicated that lack of perceived benefit from zidovudine therapy
and adverse effects of the drug were associated with discontinuation of zidovudine. No
clinical category information using CDC defined classification for HIV/AIDS were
provided in these two studies. In Muma et al.’s study (1995), only patients with mild
symptoms of HIV disease were enrolled into the study (CDC group A1, A2, B1, B2), and
no patients that met the CDC criteria for AIDS were included. They found non-adherence
was related to attitudes and beliefs about zidovudine: patients who had problems taking
zidovudine or were skeptical about the value of zidovudine were less adherent. However,
the results of these studies could be biased since patients’ beliefs, attitudes, and
adherence behaviors may vary with their disease status and experiences. The studies
conducted by Morse et al. (1991), Geletko SM, et al. (1995) and Muma RD, et al. (1995)
did not address the impact of disease severity on health beliefs and medication taking
behaviors.
A study conducted by Samet et al (1992) included patients with non-symptoms,
mild symptoms and patients with AIDS or ARC. They did find adherence behaviors were
associated with the diagnosis of AIDS or ARC and the patient belief that zidovudine
prolonged life. However, there was no consideration on the relationship between the
diagnosis (stage of HIV infection) and the belief of the patient. A study by Smith (1996)
defined stages of HIV infection according to the CDC standard classification. He found a
significant association between CD4+ cell count, having a usual source of health care,
ambulatory visits, and use of antiretrovirals at each of the three stages of HIV disease.
Smith and colleagues examined the multiple interactions between several variables and
the stage of HIV disease and did find an association between antiretroviral use and
predisposing or enabling characteristics such as gender, income, insurance status, race,
and counseling/group support attendance. However, they did not use the CDC categories
to differentiate the patients’ experience with the clinical complications of HIV nor did
they examine how health beliefs change over the course of HIV/AIDS.
Among HIV patients, the relationship of adherence and health status, including
disease severity, remains unclear. This is a problem that is not isolated to the HIV
literature (Johnson, 1993). Additional work is needed to assess this relationship.
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Summary
As can be seen from the previous review, treatment adherence behaviors are
complex and difficult to define, measure, and predict. Many factors have been identified
to influence treatment adherence. These include disease severity, personal preferences,
environmental and situational barriers, complex medical regimens, and patients’ health
beliefs. A number of theories or models have tried to summarize various factors and
provide a theoretical foundation for adherence studies. Those models are usually adapted
from theories developed to explain preventive health behaviors and use of health services
and now they have been utilized to understand or predict patient adherence to medical
regimens. The most common theory for explaining treatment adherence behaviors is the
Health Belief Model. In this model, patients’ beliefs regarding their disease, medications,
and medication taking behaviors are mainly reflected in perceptions of disease severity
and susceptibility, as well as perceived benefits and perceived barriers of treatment.
Assessing patients' beliefs regarding HIV/AIDS and its treatment should provide insight
on their adherence to HIV treatments.
Studies of treatment adherence among HIV patients to date have been limited.
None to our knowledge has examined the relationship between health beliefs, treatment
adherence, and disease severity.
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CHAPTER 3
RATIONALE AND THEORETICAL FRAMEWORK

Rationale
Patients' experiences with a disease and its treatment are likely to influence their
beliefs about the disease and the treatment regimen prescribed for them (Bandura, 1977;
Rosenstock, 1966). Patients’ beliefs, attitudes, and adherence behaviors may vary with
their disease status and experiences. Anecdotal reports of clinicians and at least two
studies suggest that patients’ adherence to antiretroviral therapy varies over the course of
the disease (Graham et al., 1994; Smith, 1996). Two possible explanations for this are
changes in patients’ health beliefs based upon their experience with the disease and its
treatment as well as an increased treatment regimen complexity associated with
increasing disease severity.

Consequently, one might suspect that the relationship

between the severity of a disease and mediction adherence is mediated by one’s health
beliefs, or simply mediated by an increased treatment regimen complexity, or both.
However, no study has verified this proposed relationship between disease severity,
health beliefs and treatment adherence.
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Theoretical Framework

This study used the following framework to examine the associations between
disease severity, health beliefs, and treatment adherence.

Clinical
Disease
Severity

Perceived Severity
Perceived Susceptibility
Perceived Benefits
Perceived Barriers

Regimen
Complexity

Adherence
Behavior

Figure 3-1. The framework for explaining the associations between disease severity,
health beliefs, and treatment adherence.

Four beliefs are drawn from the health belief model (HBM) and the revised HBM:
Perceived severity and perceived susceptibility are evaluated in a given condition. They
are the perceived seriousness of the disease and the perceived chance of disease
aggravation, made conditional on the alternative adherence or non-adherence to the
treatment. Perceived benefits are what patients perceive they will derive from their
treatment adherence behaviors. Perceived barriers are what patients perceive they will
have to overcome to adhere to their antiretroviral therapy.

Perceived barriers are

explored as nonmonetary (e.g., inconvenience of treatment, side effects of drugs,
interrupted social activities) and monetary (e.g., long-term health care costs, expenditures
on drugs) (Rosenstock, 1966; Ronis, 1992; Nau, 1997).
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Study Questions and Hypotheses

Based on the review of the literature in this area, specific research questions and
corresponding study hypotheses were formulated. Question 3, 4, 5, and 7 were
exploratory questions, thus no hypotheses were proposed.

Research Question 1:
What is the relationship of disease severity and the perceived severity of AIDS
related complications among HIV patients?
Hypothesis 1: The perceived severity of AIDS related complications among HIV
patients will increase as disease severity increases.

Research Question 2:
What is the relationship of disease severity and the conditional perceived
susceptibility of AIDS related complications among HIV patients?
Hypothesis 2: The perceived susceptibility-inaction will increase as disease
severity increases and susceptibility-action among HIV patients will decrease as disease
severity increases.

Research Question 3:
What is the relationship of disease severity and the perceived benefits of
antiretroviral therapy held by HIV patients?

Research Question 4:
What is the relationship of disease severity and the perceived barriers coming
from monetary costs of antiretroviral therapy among HIV patients?

Research Question 5:
What is the relationship of disease severity and the perceived barriers coming
from non-monetary costs of antiretroviral therapy among HIV patients?
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Research Question 6:
What is the relationship of disease severity and treatment adherence behaviors of
HIV patients?
Hypothesis 3: The adherence of antiretroviral therapy among HIV patients will
increase as disease severity increases.

Research Question 7:
To what extent are health beliefs, regimen complexity, and demographic factors
related to medication taking behaviors among HIV patients?
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CHAPTER 4
METHODS

This section presents the methods employed to achieve the research objectives. It
includes study population, sampling methods, data collection, instrument development
and validation, data analysis, and limitations.

Study Population
Sample Selection
The primary sample was drawn from the infectious disease clinic at West Virginia
University Hospital (WVUH), and the AIDS clinics at Charleston Area Medical Center
(CAMC) and University of Maryland Hospital (UMH). About 60, 30, and 150 patients
were available from WVUH, CAMC, and UMH respectively during the data collection
period. Patients were eligible for this study if they met the following criteria:
- confirmed diagnosis of HIV infection;
- using antiretroviral therapy for at least one month;
- age 18 years or older;
-

mentally competent.

Sample Size
This study used multivariate analyses of variance (MANOVA) to determine
whether four health beliefs differ across the three clinical categories (study objective 1 to
4). Hence, the clinical categories serve as 3 levels for the independent variable (clinical
status) and the health beliefs serve as the dependent variables. Unfortunately, there is no
simple equation for calculating sample size for MANOVA.

Tabachnick and Fidell

(1996) suggest that to appropriately perform a MANOVA, each cell of the MANOVA
matrix must contain at least as many subjects as dependent variables and that robustness
is enhanced when there are at least 20 subjects per level of the independent variable. If
the expected response size is achieved (n=100) with no less than 20% of subjects at any
of the three levels of the independent variable, then the MANOVA should be adequately
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robust.
The extent to which medication adherence varies across clinical category
(objective 5) was assessed with a one-way analysis of variance (ANOVA).

Power

analysis was used to estimate sample size. Power is defined as the "probability that a
statistical test will yield statistically significant results" (Cohen, 1988). The sample size
for a given study is a function of: (1) alpha, the probability of Type I error; (2) the power
for the study; and (3) the effect size expected in the study (Cohen, 1988). For most social
science research alpha is set at 0.05 and power is 0.80. Effect size (d) is estimated from
past research, pilot test data, expert opinion or rough estimates. As we have no estimate
of effect size either from past literature or theory, Cohen (1988) provides rough estimates
of effect size. To be able to detect a medium effect, say d = 0.5, and power of 80% for a
two-tailed test with alpha=0.05, the required sample size would be 64 (Table 2.4.1, pg 55,
Cohen, 1988). Past studies, in which health beliefs and medication taking behaviors of
HIV patients were examined, used between 40 and 113 subjects (Geletko, 1995; Morse,
1991; Samet, 1992; Muma, 1995). This is quite comparable to the estimated sample size
of the current study.
A multiple regression model was used to investigate the influence of regimen
complexity, demographic parameters, and health beliefs on medication-taking behaviors
(objective 6), where medication adherence is the dependent variable. Under the same
assumptions above (effect size = 0.5,  = 0.2, and  = 0.05), the required sample size
would be 73 for testing multiple correlation and individual predictors (Green, 1991).

Data Collection Procedures
A cross-sectional study design was employed using self-administered surveys.
Data were collected over a six-month period from May to December 1998 by using a
convenience sample of patients visiting the AIDS clinics.

The relatively long data

collection period was partly due to the departure of a physician in the clinic of CAMC.
Since there was only an interim MD in the clinic with a schedule of five patients per
week, it took several months to survey the majority of patients.
Patients who met the inclusion criteria were informed by the physician, or the
clinic pharmacist, about the purpose and nature of the study.
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Written information

regarding the study and the patient’s right to refusal were provided. A copy of the cover
letter is provided in Appendix D. Patients who agreed to participate were given the
written questionnaire on which their pharmacist or physician had indicated the patient's
disease stage. The patients were classified as stage A, B, or C according to the CDC
criteria (CDC, 1997). The disease category was selected based upon whether the patient
had ever experienced the indicator conditions, rather than his/her current status
(Appendix E). The subjects were allowed to complete the survey in the clinic or take it
home. Patients were also provided with a stamped return envelope and asked to seal the
survey within the envelope upon completion. The sealed envelopes were returned to
investigators at the WVU School of Pharmacy for data analysis. Hence, the physician
would not see the patient’s responses and the investigators at the School of Pharmacy
would not know the identity of the respondent thereby ensuring anonymity.

Instrument Development and Validation

Item Construction
Based on the literature review and expert panel (the clinical pharmacists and
physicians in both WVUH and CAMC), items were developed to measure disease
severity, health beliefs, regimen complexity, and medication-taking behaviors of HIV
patients. Multi-item scales were developed for medication adherence and health beliefs.
The questionnaire consists of five parts: questions about prescriptions and clinical
conditions; treatment screening questions; health beliefs assessment questions, including
assessment of perceived susceptibility, severity, benefits, and barriers; medication-taking
behavior assessment questions; and demographic questions.
Study variables are (1) disease severity, (2) regimen complexity, (3) perceived
susceptibility - inaction, (4) perceived susceptibility - action, (5) perceived severity inaction, (6) perceived severity - action, (7) perceived severity - comparative; (8)
perceived benefits, (9) perceived barriers, (10) perceived value, (11) medication
adherence, and (12) demographic variables.
The variable definitions are presented in the following sections. The final version
of the research instrument is presented in Appendix F.
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Disease Severity
In this study, disease severity was included as an independent variable. Clinic
personnel indicated the patient’s disease category as A, B, or C according to CDC
criteria. The disease category was selected based upon whether the patient had ever
experienced the indicator conditions, rather than his/her current status.

Stage A is

defined

generalized

as

asymptomatic,

acute

(primary)

HIV

or

persistent

lymphadenopathy (PGL); Stage B is defined as symptomatic conditions not included in
stage A and stage C; Stage C is defined by AIDS-indicator conditions such as Kaposi’s
sarcoma (Appendix A & B).
Regimen Complexity
The complexity or burden of a medication regimen is a function of the number of
doses per day as well as special requirements regarding the use of the medication (such as
take on an empty stomach). Currently, there is no consensus on the ideal way to assess
medication regimen complexity. This study used the number of weekly doses as an
indicator of regimen complexity. From the first item of the questionnaire, the regimen
complexity score was calculated for each patient as the sum of weekly doses for all
medications taken regularly. The dosage for the medications prescribed for use “as
needed” (i.e., PRN) were not included unless the patient indicated that they took these
medications frequently and regularly.
Perceived Susceptibility - Inaction
This variable reflects the degree to which an individual feels threatened by
aggravation of HIV infection when not adhering to his/her medication regimen. The
perception was measured on a five-point scale from 1 “very low” to 5 “very high” and
was found in the questionnaire as item 10. High susceptibility given inaction is associated
with higher probability of taking the action (adhering to the medication regimen) (Ronis,
1992).
Perceived Susceptibility - Action
This variable reflects the degree to which an individual feels threatened by
aggravation of HIV infection when he/she adheres to the prescription. This perception
was measured on a five-point scale from 1 "very low" to 5 "very high" and was found in
the questionnaire as item 11. High susceptibility given action is associated with lower
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probability of taking the action (Ronis, 1992).
Perceived Severity - Inaction
This variable shows the patients’ perception of the severity of AIDS or AIDS
related complications (ARC) when they do not adhere to their prescription. It was
measured at item 13 on a five-point likert scale (defined at the poles by the words
“strongly disagree” and “strongly agree” ). High perceived severity given inaction is
associated with higher probability of taking the action (Ronis, 1992).
Perceived Severity - Action
This variable shows the patients’ perception of the severity of AIDS or ARC
when they adhere to their prescription. It was measured at item 14 on a five-point Likert
scale (defined at the poles by the words “strongly disagree” and “strongly agree” ). High
severity given action is associated with lower possibility of taking the action (Ronis,
1992).
Perceived Severity - Comparative
This variable measures patients' perception of severity of HIV/AIDS compared to
other diseases. This construct is not contingent on patients' medication taking behaviors.
Perceived Benefits
This variable reflects the degree to which patients perceive that they can benefit
from their medication adherence behaviors. This scale consisted of three items pertaining
to the benefits of adherence behaviors (prolonging life and reducing health threat, item 15
and 18) and the perceived efficacy of the medications (item 22). A five-point Likert scale
anchored by “strongly disagree” and “strongly agree” was used.
Perceived Barriers
This variable is defined as perceived non-monetary barriers and monetary barriers
to adherence behavior. Non-monetary barriers included interrupted social activities, side
effects of drugs, psychological barriers for the treatment, medication effectiveness, and
difficult instructions. These appeared in the questionnaire as items 16, 19, 20&21, 23,
and 24 respectively. Perceived monetary barrier was measured by item 17. A five-point
Likert scale anchored by “strongly disagree” and “strongly agree” was used.
Perceived Value
This variable reflects the extent to which the respondent believes that adhering to
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the treatment is worthwhile. Conceptually, it represents the net utility of an action based
upon a tradeoff of benefits and costs (Zeithaml, 1988) and may be more closely related to
behavior intent than any other health belief (Nau, 1997). In this study, perceived value
was measured by asking subjects’ overall evaluation of their medications and medicationtaking behaviors. A five-point Likert scale (defined at the poles by the words “strongly
disagree” to “strongly agree”, and “negative” to “positive”) was used . It can be found as
questionnaire item 25 and 26.
Medication Adherence
The variables of medication adherence were measured by a four-item self-report
scale (Morisky, et al., 1986) and by self-reports of missed doses (Samet, et al., 1992).
The 4-item self-reported scale developed by Morisky was adapted in this study as
adherence measure1: (1) Do you ever forget to take your medicine? (2) Are you careless
at times about taking your medicine? (3) When you feel better do you sometimes stop
taking your medicine? (4) Sometimes if you feel worse when you take the medicine, do
you stop taking it? The second question "Are you careless at times about taking your
medicine?" in the Morisky scale was reworded to "Are you always careful about taking
your medications?" because patients may feel uncomfortable about the word “careless”.
Adherence was defined as an ordinal variable ranging from 0 - 4 with higher scores
indicating greater adherence.

Morisky et al. (1986) also suggest that a score of 4

indicates "high" adherence, 2 or 3 indicate "medium" adherence, and 0 or 1 indicate a
"low" adherence level.
The second and third measures of medication adherence operationally defined
adherence as the percentage of doses taken as prescribed during a specified time interval.
They were measured as a continuous variable and calculated by the following formula
[(prescribed doses - missed doses)  (prescribed doses)] (Samet, et al. 1992).

The

question used by Samet and colleagues to determine the number of missed doses focused
only on medication use during the last 24 hours. While this limited time frame may
enhance the accuracy of patient recall, it may not be reflective of the overall trend in the
patient’s medication adherence. Hence, patients were asked to indicate the number of
missed doses during the past two days and during the past two weeks. Responses to the
two items were compared to determine the congruency of responses.
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Subsequent

analyses were conducted using the adherence rate calculated from both approaches.
Given the exploratory nature of this study, it was appropriate to investigate the extent to
which different measures of adherence may produce different results. This has important
implications for future research in this area.
In order to compare three adherence measures, measure2 and measure3 were
further categorized into three levels - high, medium, and low. However, there was no
standard cutoff value for each level in literature, especially in HIV/AIDS studies. In a
Meta analysis conducted by Tseng (1998) and a study conducted by Samet (1992),
adherence was defined as taking > 80% of doses as prescribed. Broers et al. (1994)
defined adherence in a cohort study of drug users’ compliance with Zidovudine treatment
as good, moderate, or bad when, respectively, 80% or more, 50% to 79%, or less than
50% of prescribed treatment was taken. However, they did not mention the time interval
when they measured adherence rates.

Also, although their conclusion was that

compliance of drug users was no worse than the compliance of patients from other risk
groups, it is still not reliable to generalize these cutoff values to this study. Based on the
knowledge on this issue, HIV medication adherence for this study was defined as high,
medium, and low when, respectively, 91% to 100%, 81% to 90%, and less than 81% of
prescribed medications was taken during the past two days or during the past two weeks.
The agreement of three adherence measures was evaluated by Kappa statistics.
Kappa measures the agreement between two raters when both are rating the same object.
The difference between the observed proportion of cases in which the raters agree and the
proportion expected by chance is divided by the maximum difference possible between
the observed and expected proportions, given the marginal totals (Cohen, 1960; Landis
and Koch, 1977; Fleiss, 1981). A value of 1 indicates perfect agreement. A value of 0
indicates that agreement is no better than chance.
Demographic Variables
The following demographic variables were measured: age, gender, ethnicity,
education level, and income. Prior research has shown these variables to be influential on
health beliefs. In addition, they served as a means of assuring that the characteristics of
the respondents were consistent with the general clinic population.
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Content Validity
The clarity and face validity of the survey instrument was assessed prior to its
distribution. The face validity of the instrument used in this study was assessed via
expert review. Experts in health services research from the Department of Pharmaceutical
Systems & Policy, and clinicians from the HIV/AIDS clinics of WVUH and CAMC
reviewed the instrument to determine its clarity and appropriateness. Based upon the
expert review, a revision made to the questionnaire was the addition of the item 33:
“Have you purposefully chosen to discontinue any of your HIV medications?”. A list of
possible reasons for medication discontinuations and an open question about the reasons
were also added. This item identifies the patients who choose not to adhere to their
medications. Minor changes were made in question wording and ordering. The final
instrument is shown in Appendix F.

Construct Validity
A factor analysis was conducted to determine whether the item responses
“clustered” together consistent with the operational definitions of specified constructs or
subscales. The Health Belief Model (HBM) subscales (perceptions of susceptibility,
severity, benefit, and costs) were verified with principal axis factor analysis followed by
varimax rotation among HBM items (item 10 - 24). The correlations of items within and
between subscales were also examined. For a valid measurement scale, the correlations
within subscales should be higher than the correlations of items between subscales
(Nunnally, 1978).

Reliability
Reliability is a statistical measure of the reproducibility of the survey instrument's
data. While there are several types of reliability such as stability, equivalence, inter- and
intra-rater reliability, internal consistency (homogeneity) is particularly important for
multi-item scales (Litwin, 1995). In this study, the internal consistency of each multiitem scale (perceived benefits, perceived barriers, and adherence measure1) was
confirmed by calculating coefficient alpha and item-to-total correlations. Coefficient
alpha is the average of all the correlations between each item and the total score and

39

estimates how consistent subjects performed across items measuring the same construct
(Streiner & Norman, 1995). According to Cohen (1988), high values of the coefficient
alpha indicate a consistent performance. An alpha of greater than 0.60 is generally
considered acceptable (Robinson et al., 1991).

In addition, item-to-total correlation

statistics were used to identify problematic items in each of the instrument dimensions.
They are especially relevant when there are few items in a scale (Ferketich, 1991).
Bearden et al. (1985) considered 0.50 as an acceptable value of a corrected item-to-total
correlation to maintain an item. However, Nunnally (1978) suggests that corrected itemto-total correlations above 0.30 may be sufficient.

SPSS software also provides

coefficient alpha if the item is deleted for each item.

If there is a substantial

improvement in alpha when the item is deleted, then it may be considered problematic
and deleted to enhance the consistency of instrument scales. However, scale alpha if item
deleted is not the only excluding criteria. Decisions regarding the deletion of the item
should be based upon conceptual as well as statistical considerations. Coefficient alpha,
item-to-total correlations, and scale alpha if item deleted were calculated for each multiitem scale (perceived barriers, perceived benefits, and adherence measure1).

Data Analysis
Statistical Package for Social Sciences (SPSS - 7.5) was used for data analysis.
The data file contained seventy-two cases that represented the usable questionnaires. The
data file was meticulously checked to correct errors from data entry. Frequencies were
then obtained for all study variables to double check and clean data.
The following analytical methods were used to accomplish each of the study
objectives.
(1)

Disease Severity (DS)

Health Beliefs (HB)

(2)

(3)

Medication Adherence (MA)
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(1) MANOVA
(2) ANOVA
(3) Multiple Regression

Analytical Methods for Objective 1-4
Multivariate analysis of variance (MANOVA) was utilized to investigate the
effects of disease severity on health beliefs. MANOVA is a generalization of one-way
analysis of variance (ANOVA) to a situation in which there are several dependent
variables (DVs). It tests whether mean differences among groups on a combination of
DVs are likely to have occurred by chance (Tabachnick and Fidell, 1996). In this study,
the influences of disease severity on several health beliefs (perceived severity and
susceptibility of the disease, perceived barriers and benefits of the treatement) were
examined. Therefore, the independent variable was disease severity with three levels
(A,B,C). The health beliefs served as dependent variables. By measuring several health
beliefs at the same time instead of measuring only one of them, the effect of interactions
between these beliefs will be taken into account and inflated type I error due to multiple
tests of correlated beliefs will be avoided.
Stepdown analysis was used as a post hoc analysis for significant multivariate
effects since there are more than two levels in the multivariate main effect. Specific
comparisons among three levels of disease severity pointed out the source of the
significant difference in each health belief.
Analytical Methods for Objective 5
Analysis of variance (ANOVA) was used to compare two or more mean scores to
determine if there are any statistically significant differences among them. In this study,
the extent to which medication adherence varies across clinical category was assessed
with a one-way ANOVA. Since regimen complexity may affect medication adherence
and increase with disease severity, regimen complexity was used as a covariate in this
analysis. By doing so, the linear effect of regimen complexity upon the dependent
variable (medication adherence) is removed separately from the effect of the factor
categories (disease severity). Therefore, the main effect of disease severity was assessed
after adherence scores were adjusted for differences associated with regimen complexity.
This may increase the sensitivity of the test of main effect by reducing the interaction
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between medication adherence and regimen complexity.
Analytical Methods for Objective 6
A multiple regression model was used to investigate the influence of regimen
complexity, health beliefs, and demographic factors on medication taking behaviors.
Stepwise method was used for regression analysis in order to understand the relative
influence of each independent variable on medication adherence.

Limitations of the Study
Theoretical Issues
Measurement of regimen complexity. As mentioned before, there is currently no
consensus on the ideal way to assess medication regimen complexity. The complexity or
burden of a medication regimen is a function of the number of doses per day as well as
special requirements regarding the use of the medication (such as “take on an empty
stomach”).

However, the literature is devoid of any reliable and valid means of

calculating the burden of special requirements. This study used the number of weekly
doses for all relevant prescribed medications as an indicator of regimen complexity. The
limitations of this simple measure of regimen complexity are obvious (e.g., the
measurement ignored the special requirements along with the use of medications and
only reflected a maximized regimen weekly dosage instead of accurately reflecting the
regimen complexity). In addition, since the main objectives of this study were to
investigate the relationship of disease severity and health beliefs, this simple measure
may be a reasonable way to estimate regimen complexity in this preliminary study.
Measurement of medication adherence. Adherence to the prescribed medications
for HIV/AIDS was measured by a four-item self-reported scale (Morisky, et al, 1986),
and by self-reports of missed doses (Samet, et al. 1992). Patient self-administered
questionnaires were used to obtain a patient's subjective evaluation of his or her
medication adherence behaviors. It may have induced some error due to recall bias and
social desirability. However, by comparing the results obtained from multiple measures, a
rough estimate of the accuracy or at least consistency or these measures can be made.
The other two measures of adherence used in this study can only reflect the
missing doses. Incorrect dosage intervals can not be detected by these measures.

42

Definitions and measurements of health beliefs.

Perceived susceptibility -

inaction, perceived susceptibility - action, perceived severity - inaction, perceived
severity - action, perceived benefits, perceived barriers, and perceived value were defined
and measured as health beliefs in this study. It is very difficult to distinguish perceived
severity - inaction and perceived severity - action for a serious disease such as HIV
infection. Furthermore, the items used to measure each perception may not perfectly
represent the constructs in theory. While a factor analysis was conducted to verify the
operational definition of each subset of items, a strong relationship among a set of items
may be due to strong influence of one item (or some items) over another instead of their
representing the same construct.
Causality. The statistical analyses used in this study (MANOVA, ANOVA, and
multiple regression) revealed the relationship between disease severity, health beliefs,
and medication adherence. However, they did not imply that the relationships were
causal.
Practice Issues
Sample size. The number of subjects was quite small in this study. Most patients
were in stage A. Some patients in stage B or C were too sick to complete the survey. To
avoid this problem, later studies may use a larger sample pool for patients in stage B and
C.
Influence of study settings.

This study was conducted in clinical sites. The

clinical pharmacist, social worker, or physicians introduced and distributed the survey to
patients. Thus some patients may feel predisposed to give more desirable responses
(such as a higher adherence rate and positive value to the treatment) despite being
informed that their individual responses would not be shared with the clinicians.
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CHAPTER 5
RESULTS

Subjects
Seventy-two patients completed the survey, representing 30.0% of the 240
patients who had scheduled clinic appointments during the six months data collection
period.

According to the experience of clinic pharmacists, the majority of non-

respondents either forgot to complete or send the survey, or were too sick to complete the
survey.
Demographic characteristics of the sample are shown in Table 5-1. Most patients
were white (52.9%) male (73.1%), with an age between 25 and 44 years old (78.0%).
About forty-three percent of respondents had college or graduate education and 70.6% of
respondents earned less than 20,000 a year. Regarding the type of insurance coverage,
Medicaid was the major payer for the patients surveyed (42.9%), followed by private
insurance companies (22.1%) and the Ryan White Consortium (14.3%). Only three
patients (3.9%) reported that they had to pay for HIV medications mainly by themselves.
Clinical characteristics of the sample are presented in Table 5-2. The distribution
of patients categorized in each disease stage was not equal. Most patients were in the
first (asymptomatic) and third (AIDS/ARC) stage (44.5% and 34.7%, respectively),
compared to 20.8% of patients in stage two (HIV-symptomatic). There are about equal
numbers of patients in asymptomatic (A) stage and symptomatic (B and C) stage (44.5%
and 55.5%, respectively). More than half of the patients (59.1%) reported taking 3 to 5
medications, and 19.8% of the patients reported taking even more (>=6) medications. In
addition, more than half (59.2%) of the respondents visited their physician once every 2 3 months or every 4 - 5 months, and only 2.8% of the patients visited their physician
more than once a month. Nearly all respondents (97.2%) indicated that they had been
taking medications for HIV/AIDS for more than four months.
Patients were also asked to indicate their current and lowest CD4+ counts, as well
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as current and highest viral load. Five patients (7.2%) did not know their current CD4+
counts, 9 patients (13.0%) did not know their lowest CD4+ counts, 17 patients (25.0%)
did not know their recent viral load, and 23 patients (33.8%) did not know their highest
viral load ever.
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Table 5-1. Demographic Characteristics of Respondents (N = 72)

CHARACTERISTIC

FREQUENCY

PERCENT ( %)

Male
Female

49
18

73.1
26.9

18 - 24 years
25 - 34 years
35 - 44 years
45 or older

1
21
32
14

1.5
30.9
47.1
20.5

Ethnicity
White
Black or African-American
Other

36
31
1

52.9
45.6
1.5

Education
Less than 9th grade
9th to 12th grade
Some college, no degree
Bachelors degree
Graduate or professional degree

2
37
15
8
6

2.9
54.4
22.1
11.8
8.8

31
17
6
11
3

45.6
25.0
8.8
16.2
4.4

33
17
11
3
3
10

42.9
22.1
14.3
3.9
3.9
12.9

Gender

Age

Income
Less than $10,000
10,000 - 19,999
20,000 - 29,999
30,000 - 49,999
50,000 or more
Type of Major Insurance
Medicaid
Private Insurance
Ryan White Consortium
Drug Company
Self-Pay
Other
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Table 5-2. Clinical Characteristics of Respondents (N = 72)

CHARACTERISTIC

FREQUENCY

PERCENT ( %)

Disease Category
A
B
C

32
15
25

44.5
20.8
34.7

Number of Medications
Less than 3
3
4
5
6
More than 6

15
14
12
16
6
8

21.1
19.7
16.9
22.5
8.6
11.2

Visit Frequency
More than once a month
Once a month
Once every 2 - 3 months
Once every 4 - 5 months
Once every half a year or longer

2
24
35
7
3

2.8
33.8
49.3
9.9
4.2

Duration of Therapy
2 - 3 months
4 - 6 months
More than 6 months

2
6
62

2.8
8.6
88.6
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Study Variables

Disease Severity
Clinic personnel indicated the patient’s disease category as A, B, or C on the
questionnaire. The results were reported in Table 5-2.
Perceived Severity - Inaction
This variable showed the patients’ perception of the severity of AIDS or AIDS
related complications (ARC) when they did not adhere to their prescription regimen. The
mean and standard deviation of the perception score were 4.13 and 0.97, respectively
(Table 5-3a). A mean score above four with a small standard deviation suggested that
most patients perceived they would become very sick if they did not take their
medications as prescribed.
Perceived Severity - Action
This variable showed the patients’ perception of the severity of AIDS or AIDS
related complications (ARC) when they adhered to their prescription regimen. The mean
and standard deviation of the perception score were 2.52 and 1.04, respectively (Table 53a). Although 54.9% of the patients disagreed or strongly disagreed with the statement,
some patients (29.6%) were neutral regarding their becoming very sick even if they took
their medications as prescribed.
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Table 5-3a. Study Variables - Health Beliefs

Variables and Items

Strongly
Disagree Disagree
(%)
(%)

Neutral
(%)

Agree
(%)

Strong
Agree
(%)

Mean + Std.Dev. *

Perceived Severity - Inaction:
I'll become very sick if I'm not adherent
Perceived Severity - Action:
I'll become very sick if I'm adherent

1.4

7.0

11.3

38.0

42.3

4.13+0.97

14.1

40.8

29.6

9.9

5.6

2.52+1.04

Perceived Severity - Comparative
Compared to other illnesses, HIV/AIDS is very serious

5.6

4.2

7.0

26.8

56.4

4.28+1.11

Perceived Benefits:
Adherence can prolong my life
Adherence can decrease the chances of getting worse
HIV medications I'm taking can improve my health

2.8
5.6
2.8

0.0
4.2
0.0

5.6
21.1
19.7

39.4
31.0
42.3

52.1
38.0
35.2

4.38+0.83
3.92+1.13
4.07+0.90

Perceived Barriers:
Interfering a great deal with my normal activities
Making me feel more nervous or depressed than usual
Causing annoying side effects
Dealing with the side effects is stressful
More effective if I take medications. only when I feel bad
Difficult to follow doctors' instructions on medications
HIV medications are too expensive for me

21.1
12.6
5.7
10.0
53.5
36.6
12.9

36.6
26.8
12.9
14.3
35.2
36.6
17.1

15.5
22.5
18.6
20.0
4.2
12.7
10.0

14.1
26.8
40.0
44.3
1.4
5.6
28.6

12.7
11.3
22.8
11.4
5.6
8.5
31.4

2.61+1.32
2.97+1.23
3.61+1.15
3.33+1.16
1.70+1.03
2.13+1.22
3.49+1.42

Perceived Value:
Taking HIV medications is worth the hassle

4.2

4.2

8.5

36.6

46.5

4.17+1.04
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Table 5-3a. (CONTD.) Study Variables - Health Beliefs

Variables and Items
Perceived Value:
Experiences with HIV medications overall have been:

Somewhat
Negative Negative
(%)
(%)
2.9

1.4

Neutral
(%)
7.2

Somewhat
Positive Positive Mean + Std.Dev. *
(%)
(%)
29.0

59.4

4.41+0.91

Mean + Std.Dev. *

Very
Low
(%)

Low
(%)

Intermediate
(%)

High
(%)

Very
High
(%)

Perceived Susceptibility - Inaction:
Chances of getting worse if not adherent

3.1

1.6

21.9

34.3

39.1

4.05+0.98

Perceived Susceptibility - Action:
Chances of getting worse if adherent

30.4

33.3

26.1

7.2

2.9

2.19+1.05

Variables and Items

* For all subscales, higher scores represent greater amounts of the construct.
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Perceived Severity - Comparative
This item asked patients how severe they thought HIV/AIDS was compared to
other illness. Most patients (83.2%) disagreed or strongly disagreed with the statement
"Compared to other illness, HIV/AIDS is NOT very serious" (Table 5-3a).
Perceived Benefits
The perceived benefits were operationally defined as the degree to which patients
perceive that they can benefit from their medication adherence behaviors.

It was

comprised of three items, each of which was measured on a five-point Likert scale (Table
5-3a). For all three items, the means were higher than the midpoint, especially for the
item "Taking medications as prescribed can prolong my life" (mean = 4.38, S.D. = 0.83).
This suggests that most patients believed adhering to their medications was beneficial.
Perceived Barriers
The perceived barriers were defined as both non-monetary and monetary barriers
to adherence behavior. The non-monetary barriers were measured by five items and the
perceived monetary barrier was measured by one item (Table 5-3a). The majority of
patients agreed or strongly agreed that HIV medications caused annoying side effects,
that dealing with the side effects was stressful, and HIV medications were very
expensive. Also, the vast majority of the patients disagreed or strongly disagreed with the
statements "HIV medications will work more effectively if I take them only when I am
feeling bad" and "It is difficult to follow doctors' instructions on HIV medications".
However, there was considerable variation in perceptions about "Taking HIV
medications or having side effects from them makes me feel more nervous or depressed
than usual" (mean = 2.97, S.D. = 1.23) and "Taking HIV medications interferes a great
deal with my normal activities" (mean = 2.61, S.D. = 1.32).
Perceived Value
Perceived value was defined as the extent to which the patient believed that
adhering to his/her treatment was worthwhile. For the item that stated “Taking my HIV
medications is worth the hassle”, the responses were scored on a five-point agreement
scale. The mean and standard deviation of the perceived value score were 4.17 and 1.04,
respectively (Table 5-3a).

Another variable measuring perceived value stated as

“Overall, would you say your experiences with HIV medications have been___”. The
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responses were scored on a five-point scale with 1 representing “negative” and 5
representing “positive”. The mean and standard deviation of the perceived value score
were 4.41 and 0.91, respectively (Table 5-3a). The mean scores of both items were close
to 5, which indicates that most patients believe that taking their medications is
worthwhile.
Perceived Susceptibility - Inaction
This variable measured the degree to which a patient felt threatened by
aggravation of HIV infection (i.e. developing AIDS-related complications) when not
adhering to his/her medication regimen. Most patients (73.4%) rated their chances of
getting worse "high" or "very high" if they did not take HIV medications as prescribed.
The mean and standard deviation of the perception scores were 4.05 and 0.98,
respectively, on a five-point scale (Table 5-3a). The mean was relatively high, which
suggests that patients generally perceive the probability of getting worse is high if they do
not adhere to their medication regimens.
Perceived Susceptibility - Action
This variable measured the degree to which a patient felt threatened by
aggravation of HIV infection (i.e. developing AIDS-related complications) when taking
his/her medication regimen as prescribed. Nearly two-thirds (63.7%) of the patients rated
their chances of getting worse as low or very low if they take HIV medications as
prescribed. The mean and standard deviation of the perception score were 2.19 and 1.05,
respectively (Table 5-3a). A mean below the midpoint of the scale suggests that patients
generally perceive the probability of getting worse is low if they adhere to their
medication regimens.
Regimen Complexity
The number of weekly doses was calculated as an indicator of regimen
complexity. The number of weekly doses ranged from 14 to 147 with a mean and
standard deviation of 54.94 and 24.26, respectively (Table 5-3b). Thus, patients took
about eight doses a day on average.
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Table 5-3b. Study Variables - Regimen Complexity and Medication Adherence

Variables

Range

Mean + Std. Dev.*

Regimen Complexity

14 - 147

54.94+24.26

Adherence Measure1

1-4

2.90+0.93

Adherence Measure2

0% - 100%

93.10+15.20

Adherence Measure3

0% - 100%

96.39+12.82

* For all scales, higher scores represent greater amounts of the construct.
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Medication Adherence
Measure1. Medication adherence was first measured by a four-item scale with
higher scores indicating greater adherence. The score was based upon the number of
“No” responses (recoded for #2) and reflected the degree to which a patient adhered to
his/her medications. More than one third of the patients (35.2%) reported that they did
not ever forget to take their medicine; 83.1% patients said they were always careful about
taking their medicine; 87.3% patients would not stop taking their medicine when they
feel better; and 84.5% patients would not stop taking their medications even if they feel
worse when they take the medicine. The mean and standard deviation of the scale were
2.90 and 0.93 (Table 5-3b).
Measure1 was developed by Morisky et al. (1986). They suggest that a score of 4
indicates "high" adherence, 2 or 3 indicate "medium" adherence, and 0 or 1 indicate a
"low" adherence level. In this study, 28.2% of the patients were categorized as high
adherence, 62.0% as medium adherence and only 9.8% as low adherence.
Measure2 & Measure3. The second and third measure of medication adherence
defined adherence as the percentage of doses taken as prescribed during a specified time
interval. The average missed doses during the past two days and the past two weeks were
0.8 and 2.3, respectively. According to the formula [(prescribed doses - missed doses) 
(prescribed doses)] * 100% (Samet, et al. 1992), the medication adherence score ranged
from 0% to 100% with a mean of 93.1% during the past two days and ranged from 0% to
100% with a mean of 96.4% during the past two weeks (Table 5-3b).
In order to compare the three adherence measures, measure2 and measure3 were
further categorized into three levels - high, medium, and low. Based on our knowledge
on this issue, we defined HIV medication adherence as high, medium, and low when,
respectively, 91% to 100%, 81% to 90%, and less than 81% of prescribed medications
was taken during the past two days or during the past two weeks.
Agreement of three measures. The conformity of the three adherence measures
was evaluated by Kappa statistics (Table 5-4). Kappa measures the agreement between
two raters when both are rating the same object.

A value of 1 indicates perfect

agreement. A value of 0 indicates that agreement is no better than chance. Results
showed that measure1 and measure3 had lowest agreement (Kappa = 0.03, p = 0.34).
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Measure1 and measure2 were also incompatible (Kappa = 0.07, p = 0.24). However, the
agreement between measure2 and measure3 was statistically significant albeit not ideal
(Kappa = 0.26, p < 0.001).
Intentional discontinuation of the medications. Patients were also asked whether
they had purposefully chosen to discontinue any of their HIV medications and why.
Most of them (79.4%) reported they have never purposefully stopped taking their HIV
medications.

For those who had discontinued their HIV medications on purpose,

intolerable side effect was the most common reason (100%). Additional reasons included
"they are expensive" (14%), "taking them is complicated and inconvenient for me"
(14%), "refilling prescriptions or regular clinic check is a burden on me" (7%), and "I
heard/observed worsening of HIV symptoms in others taking their medications" (14%).
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Table 5-4. Agreement of Three Measures for Medication Adherence

Kappa

Asymp.
Std.Errora

Tb

p

Measure1-Measure2

0.07

0.06

1.18

0.24

Measure1-Measure3

0.03

0.03

0.96

0.34

Measure2-Measure3

0.26

0.12

4.18 < 0.001*

a. Not assuming the null hypothesis.
b. Using the asymptotic standard error assuming the null hypothesis.
* Kappa is significantly different from zero when alpha = 0.05.
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Construct Validity
Construct validity of health beliefs was assessed by conducting a principal
component analysis followed by varimax rotation. Five dimensions of health beliefs
were extracted and accounted for 71.3% of variance in beliefs about HIV medications
and adherence behaviors (Table 5-5).

These dimensions measured: perceived non-

monetary barriers of taking HIV medications as prescribed; perceived benefits of HIV
medications or adherence behaviors; perceived monetary cost of HIV medications;
concepts related to risks of non-adherence; and perceived comparative severity of
HIV/AIDS. The variance accounted for by these five factors were 24.4%, 15.3%, 12.6%,
9.7%, and 9.3%, respectively.
The factor analysis suggests that the patients’ perceptions of monetary barriers
and non-monetary barriers were conceptually distinct. It also reveals that several items
clustered because of their relationship to either the benefits of adherence or the risks of
non-adherence.

The items measuring perceived susceptibility-action and perceived

susceptibility-inaction were under the dimensions of adherence benefits and nonadherence risks, respectively. This may be due to the wording of the questions. Unlike
what was expected, item 23 “HIV medications will work more effectively if I take them
only when I am feeling bad” and item 24 “It is difficult to follow doctors’ instructions on
HIV medications” had low factor loadings (-0.06 and 0.28, respectively), which means
they do not reflect well the concept of barriers as defined in this study. Similarly, item 22
“The HIV medications that I’m taking will improve my health” was also separate from
other items measuring treatment benefits (factor loading = 0.15).
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Table 5-5. Factor Structure of Beliefs about HIV/AIDS and the Treatment

Factors and Items*

Loading

Factor 1 - Perceived Barriers (non-monetary)
Item
21. Dealing with the side effects is stressful
20. Medications make me feel more nervous or depressed
19. Medications cause annoying side effects
16. Medications interfer a great deal with my normal activities
[ 24.38% of variance, Eigenvalue = 3.17 ]
Factor 2 - Benefits of Adherence
Item
15. Adherence can prolong my life
18. Adherence can decrease the chances of getting worse
11. Chances of getting worse if adherent
[ 15.27% of variance, Eigenvalue = 1.99 ]
Factor 3 - Monetary Barriers
17. HIV medications are too expensive for me
[ 12.55% of variance, Eigenvalue = 1.63 ]
Factor 4 - Risks of Non-Adherence
Item
10. Chances of getting worse if not adherent
23. More effective if I take meds. only when I feel bad
[ 9.71% of variance, Eigenvalue = 1.26 ]
Factor 4 - Perceived Comparative Severity
Item
12r. Compared to other illnesses, HIV/AIDS is very serious
[ 9.35% of variance, Eigenvalue = 1.22 ]

* Only loading scores above 0.60 (absolute value) are reported.
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0.91
0.87
0.86
0.67

0.78
0.77
-0.71

0.73

0.84
-0.61

0.82

Scale Reliability

Multi-item scales were used to measure health beliefs (perceived benefits and
perceived barriers) and treatment adherence measure1.

Given that the study is

exploratory, an alpha estimate of 0.60 and above was considered reasonable in this study.
Scale statistics and reliability coefficients for multi-item scales are presented in Table 5-6
and 5-7. The Perceived Benefits scale included three items. The item "HIV medications
I'm taking can improve my health" had a low item-total correlation (0.19). Also, the
Alpha could be increased from 0.52 to 0.62 if the item was deleted. Therefore, this item
was excluded from the scale of perceived benefits.

The final Alpha, or Pearson

correlation coefficient, for this two-item scale was 0.62. The Perceived Barriers scale
only included non-monetary barriers since the factor analysis suggested the perceived
monetary cost and non-monetary barriers should be separated as two different
components. Item-total correlations for the item “HIV medications will work more
effectively if I take them only when I am feeling bad” and “it is difficult to follow
doctors’ instructions” were very low (0.02 and 0.24, respectively). It indicated that these
items were different from other items measuring barriers. Thus, they were deleted from
the scale. The final Chronbach’s alpha was 0.85, which was relatively high.
In contrast to the results of a prior study (Morisky et al., 1986), Adherence
Measure1 had very low reliability ( = 0.38). The item-total correlations for the four
items were also very low. It indicated that this measure may not be an ideal measure of
adherence.
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Table 5-6. Item-Total Correlation and Corrected Alpha

Item

Item - Total
Alpha If
Correlation Item Deleted

Perceived Benefits
Adherence can prolong my life
Adherence can decrease the chances of getting worse
HIV medications I'm taking can improve my health

0.42
0.43
0.19

0.31
0.24
0.62*

Perceived Barriers (non-monetary)
Dealing with the side effects is stressful
Making me feeling more nervous or depressed than usual
Causing annoying side effects
Interfering a great deal with my normal activities
Difficult to follow doctors' instructions on HIV medications

0.70
0.69
0.59
0.52
0.24

0.60
0.59
0.63
0.65
0.78*

More effectively if I take them only when I am feeling bad

0.02

0.74*

Medication Adherence Measure1
Do you ever forget to take any of your meds.
Are you always careful about taking your meds.
When you feel better do you sometimes stop taking your meds.
Sometimes if you feel worse when you take the medication,
do you stop taking it?

0.28
-0.01
0.29
0.29

0.21
0.51
0.23
0.22

* Item deleted from the final scale.
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Table 5-7. Scale Statistics and Reliability Coefficients

Multi-item scales

Number of Items

Scale
Mean + S.D.

Alpha

Perceived Benefits

2

8.30 + 1.69

0.62

Perceived Non-monetary Barriers

4

12.65 + 3.99

0.85

Medication Adherence1

4

2.90 +0.93

0.38
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Objective A to D Results
The first objective of the study was to compare the perceived severity of AIDS
related complications among HIV patients in different disease stages.

It was

hypothesized that the perceived severity of AIDS related complications held by HIV
patients would increase as disease severity increased. The second objective of the study
was to compare the perceived susceptibility to AIDS related complications held by HIV
patients in different disease stages.

It was hypothesized that conditional perceived

susceptibility of AIDS related complications held by HIV patients would increase as
disease severity increased. The third objective of the study was to compare the perceived
benefits of antiretroviral therapy held by HIV patients in different disease stages. The
fourth objective of the study was to compare the perceived barriers to medication
adherence held by HIV patients in different disease stages. The monetary and nonmonetary barriers were examined separately.
MANOVA was conducted to achieve these four objectives.

The mean and

standard deviations of health beliefs across three disease severity categories are presented
in Table 5-8. Using  = 0.05, the multivariate tests did not show significant effects of
disease severity on patients’ health beliefs (Wilks’  = 0.76, p = 0.21). More specifically,
there was no statistically significant difference in patients’ perceived severity of
HIV/AIDS and perceptions of benefits and barriers of the treatment across three disease
stages. However, tests of between-subjects effects revealed that disease severity did
influence patients' perception of susceptibility-inaction (F = 3.38, p = 0.04). Further Post
Hoc tests (LSD method) showed there were significant differences in perceived
susceptibility-inaction between patients in stage A and C (p = 0.01). That means patients
who have greater experience with the disease are more likely to consider themselves at
risk for complications if they don’t take their medicine.
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Table 5-8. Health Beliefs among Patients in Different Disease Stages*

Health Beliefs

Stage A
M + SD

Stage B
M + SD

Stage C
M + SD

F

p

Perceived Severity

4.41+0.84

3.79+1.58

4.55+0.83

2.39

0.10

Susceptibility - action

2.19+1.00

1.79+0.89

2.25+0.97

1.08

0.35

Susceptibility - inaction

3.78+0.89

4.07+0.83

4.45+0.89

3.38

0.04**

Perceived Benefits

8.30+1.61

8.50+1.34

8.15+2.13

0.17

0.85

Perceived Non-monetary Barriers 13.78+3.95

11.29+4.20 12.65+3.92 1.83

0.17

Perceived Monetary Barriers

3.36+1.34

0.91

3.56+1.40

3.55+1.61

* For all subscales, higher scores represent greater amounts of the construct.
** The mean difference is significant at = 0.05.
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0.10

Objective E Results
The fifth objective of the study was to examine medication adherence of HIV
patients with antiretroviral therapy in different disease stages. It was hypothesized that
the adherence of antiretroviral therapy among HIV patients would increase as disease
severity increased.
Means and Standard Deviations of medication adherence across three disease
stages are shown in Table 5-9. It revealed that the mean level of medication adherence
did increase as disease severity increased across all adherence measures.
Simple factorial ANOVA was used to assess the significance of the effects of
disease severity on patients’ medication adherence. In addition, regimen complexity was
included in the analysis as a covariate to control for its influence on adherence (Table 510). The dependent variable was based on the adherence score obtained by adherence
measure2 (missed doses in past two days). Adherence measure2 was utilized in the
analysis because the following reasons:
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Table 5-9. Medication Adherence among Patients in Different Disease Stages

Medication Adherence

Stage A
M + SD

Stage B
M + SD

Stage C
M + SD

Measure1

2.74+0.82

3.08+0.86

3.13+0.97

Measure2

90.29+12.82

96.83+6.30

98.84+3.20

Measure3

96.41+6.10

98.42+2.76

99.32+1.12
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Table 5-10. Effects of Disease Severity on Medication Adherence

Adherence (Measure2)

Disease stage A,B,C
F
p*

Asymptomatic v.s. Symptomatic
F
p*

Main Effects: Disease Severity

3.85

0.026

7.72

0.007

Covariate: Regimen Complexity

3.80

0.046

4.17

0.045

Model

5.43

0.002

8.22

0.001

* All effects are significant at p = 0.05.
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1) Only Measure2 had significant correlations with the health beliefs and highest R2
(p=.006, R2=.48);
2) Measure2 had significant agreement with measure3;
3) Measure1 had a very low reliability coefficient ( = 0.38) in this study.
The unique or main effect of disease severity on medication adherence was
significant among three disease stages (F = 3.85, p = 0.03).

However, the mean

adherence score for stages B and C were very close (Table 5-9). Thus, we combined
those patients in stages B and C (symptomatic) and compared this symptomatic group to
the asymptomatic patients in stage A. This resulted in a more dramatic difference in
adherence scores (F = 7.72, p = 0.007). Consequently, patients with some experience of
HIV/AIDS complications were more adherent to their medications compared to patients
who had never experienced complications.

Objective F Results
The final objective of this study was to investigate the influence of regimen
complexity and health beliefs on patients’ self-reported medication adherence.

In

addition, the effects of demographic characteristics on patients' adherence were
examined.
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Table 5-11. The Relationship between Medication Adherence and Health Beliefs,
Regimen Complexity, and Demographic Factors

Variables

Beta

t

p

Included Variables
Susceptibility-inaction
Difficulty in following doctors'
instructions

0.36
-0.33

2.92
-2.69

0.005
0.009

-0.19
-0.16
0.10
0.04
-0.19
0.06
-0.01
0.07
-0.02
0.11
0.04
-0.09
0.09

-1.52
-1.28
0.77
0.00
-1.48
0.44
-0.09
0.53
-0.17
0.86
0.34
-0.69
0.71

0.14
0.21
0.44
0.99
0.15
0.66
0.93
0.60
0.96
0.39
0.73
0.50
0.48

Excluded Variables
Non-monetary Barriers
Susceptibility-action
Perceived Severity
Perceived Benefits
Monetary Barriers
Regimen Complexity
Age
Gender
Race
Education
Income
Improving my health
More effective when I feel bad

* Using p = 0.05 as entry criteria in stepping method.
* Regression Model: F = 8.00, p = 0.001.
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A multiple regression analysis using a stepwise method was conducted to achieve
objective F. Individual health beliefs were entered into the regression model in addition
to summated scale scores. Results are presented in Table 5-11.

Two significant

predictors of patients’ medication adherence were detected. Perceived susceptibilityinaction was positively associated with their adherence ( = 0.36, t = 2.92, p < 0.01). The
higher perceived chance of getting worse if not taking their medications as prescribed, the
more likely that patients would be adherent. Medication adherence was also negatively
related to the difficulty of following doctor's instructions on HIV medications ( = -0.33,
t = -2.69, p < 0.01). The more difficult to follow doctors' instructions felt by the patient,
the less he/she was adherent to the treatment.
Other health beliefs such as scales of perceived barriers and benefits, perceived
susceptibility-action, and perceived severity did not significantly affect medication
adherence. In addition, results of the regression analysis showed that regimen complexity
alone was not a significant predictor of patients' medication adherence. Finally, no
demographic factors such as age, gender, race, education, and income were found to
relate to medication adherence. The final regression model thus included two predictors:
perceived susceptibility-inaction and difficulty in following doctors' instructions on HIV
medications (F = 8.00, p < 0.01).

Influence of Ethnicity on Health Beliefs
The primary sample was drawn from three sites: the infectious disease clinic at
West Virginia University Hospital (WVUH), and the AIDS clinics at Charleston Area
Medical Center (CAMC) and University of Maryland Hospital (UMH). There were
substantial differences between patients from West Virginia and Maryland. Table 5-12
shows an overall comparison of the three sites on demographic and clinical
characteristics of patients. There was no statistically significant difference between the
three sites on age, income, gender, disease severity, medication numbers, regimen
complexity, and on-therapy time. However, race, education level, and visit frequency
were significantly different between the three sites (p < 0.05). The respondents from
WVUH and CAMC were predominately white and male, whereas the respondents from
UMH were predominately African-American and included many females (Table 5-13).
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The sample was consistent with the study population of each clinic in race and gender
distribution as estimated by clinic staff.
In order to obtain a better understanding of the influence of ethnicity on health beliefs
and medication adherence, white patients and African-American patients were compared
in their health beliefs, medication taking behaviors, and awareness of disease. Table 5-14
shows there was no statistically significant difference between white and black patients in
most health beliefs about HIV/AIDS and its treatment except for perceived severity,
perceived interference with normal activities, and reserving medications for bad
conditions. Compared to white patients, African-American patients perceived HIV/AIDS
to be less serious; perceived that taking medications interfered less with normal activities;
were less stressed by medication side effects; and were less likely to disagree that
medications "work more effectively if I take them only when I am feeling bad". The
African-American respondents were also less likely to perceive medications as being too
expensive.
It is important to note that nearly all of the African-American respondents were at
UMH.

Hence, the racial differences in responses could actually be due to other

characteristics of the site (e.g., the process of care).
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Table 5-12. Comparison of Three Sites on Demographic and Clinical
Characteristics

Characteristics

Test Statistics

p

Demographics
Age

X2 = 5.46

0.49

Gender

X2 = 5.61

0.06

2

Race

X = 56.55

< 0.0001*

Education

X2 = 18.90

0.02*

Income

X2 = 12.23

0.14

Clinical Characteristics
Disease Severity

X2 = 7.02

0.13

Number of Medications
Regimen Complexity
Visit Frequency

F = 0.28
F = 0.50
X2 = 18.57

0.76
0.61
0.02*

On-therapy Time

X2 = 7.73

0.26
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Table 5-13. Patients' Composition of Three Sites by Gender and Race

Race

WVUH
Male Female

CAMC
Male Female

UMH
Male Female

Total

White

18

3

11

3

1

0

36

African-American

1

0

1

0

15

12

29

Other

0

0

0

0

1

0

1

Total

19

3

12

3

17

12
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Table 5-14. Medication Adherence and Health Beliefs by Race

White
African-American
M + S.E.
M + S.E.

F

p

Medication Adherence (Measure2)

96.65+0.97

90.47+3.89

2.89

0.09

Susceptibility - inaction

4.18+0.16

3.88+0.19

1.58

0.21

Susceptibility - action

2.24+0.16

1.88+0.19

2.12

0.15

Perceived Severity

4.64+0.18

3.79+0.21

9.47

.003*

Perceived Benefits
- prolonging life
- preventing getting worse
- improving health**

4.39+0.16
4.15+0.18
4.06+0.16

4.29+0.18
3.71+0.22
3.88+0.19

0.18
2.45
0.54

0.68
0.12
0.46

Perceived Non-monetary Barriers
- interfering activities
- causing annoying side effects
- making me feel nervous/depressed
- making me feel stressful
- difficult to understand instructions**

3.00+0.22
3.91+0.19
3.27+0.21
3.76+0.19
2.09+0.22

2.21+0.26
3.50+0.22
3.00+0.25
3.07+0.22
2.33+0.26

5.32
2.03
0.69
4.21
0.51

0.03*
0.16
0.41
0.05
0.48

- taking them only when I feel bad**

1.49+0.19

2.08+0.22

4.27

0.04*

3.85+0.24

3.08+0.29

4.14

0.05

Perceived Monetary Barriers

* For all subscales, higher scores represent greater amounts of the construct.
** Items deleted from the final "Benefit" or "Barriers" scale.

73

Due to the fact that the influence of disease severity on health beliefs may be
biased by race, MANOVA was conducted to examine whether there was an interaction of
disease severity and race. By using disease severity and race as two independent factors,
the individual effects and their interactions can be detected. Results showed that there
was no interaction between disease severity and race (Wilks’  = 0.72, p = 0.20) and
further confirmed the reports in Table 5-8 and Table 5-14: disease severity alone had no
significant influence on patients’ health beliefs except for susceptibility-inaction and
African-American patients had significantly lower perceived severity of HIV/AIDS and
lower perceived treatment barriers related to side effects, interference with normal
activities and monetary cost.
Although white patients had a higher mean score of medication adherence than
black patients, the difference was not significant (p = 0.09). In other word, race had no
significant relationship with medication adherence in this study.

Regarding the

awareness of disease, 17% of African-American patients didn't know their current CD4+
counts, whereas all white patients reported their current CD4+ count; 24% of AfricanAmerican patients didn't know their lowest CD4+ counts ever, compared to 5% of white
patients; 45% African-American patients didn't know their recent viral load, compared to
11% of white patients; and finally, 48% African-American patients didn't know their
highest viral load ever, compared to 23% of white patients.
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CHAPTER 6

DISCUSSIONS AND RECOMENDATIONS

This chapter presents a review of this study and discusses its major findings.
Where applicable, conclusions are drawn regarding those findings.

In addition, the

implications of this study are stated and recommendations for future research are made.

Study Review
The advent of highly active antiretroviral therapy (HAART) means that more HIV
patients need to take multiple medications for longer periods (Tseng, 1998). In addition,
many antiretrovirals may have adverse effects, rigorous dosage and administration
requirements, be associated with numerous drug interactions, and be very expensive
(Deeks et al., 1997; Swindells and Gendelman, 1996). Medication adherence among HIV
patients becomes a very serious issue. However, there is limited research addressing this
issue, especially a lack of theory-based studies regarding medication use among patients
with HAART. In addition, since symptoms can vary greatly in frequency and severity
among HIV patients (Centers for Disease Control, 1997; Tseng, 1998), there is likely to
be considerable variability amongst HIV patients’ perceptions of disease severity and
progression as well as perceived benefits and costs of treatment. Patients’ medication
adherence may also be influenced by their disease experiences. However, very little is
known about how disease severity affects patients’ beliefs about disease and medications
and patients’ medication taking behaviors.
The goal of this study was to investigate the relationship of disease severity,
health beliefs and medication taking behaviors among HIV/AIDS patients. The health
belief model (HBM) was used to build the theoretical framework for this study.
Consistent with the work of Ronis (1992) and Nau (1997), the perceived susceptibility
was measured as "conditional" based upon the subjects' behavior. Additionally, the
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perceived barriers component was measured as non-monetary (e.g., inconvenience of
treatment, side effects of drugs, interrupted social activities) and monetary components
(e.g., expenditures on drugs).
The association between disease severity, health beliefs and medication adherence
was examined using a combination of clinician reported and patient self-reported data.
Furthermore, this study enrolled patients in all three CDC categories for HIV/AIDS and
addressed patients’ adherence to the entire drug regimen rather than just one drug as in
many studies (Geletko et al., 1995; Muma et al., 1995; Samet et al., 1992; Broers et al.,
1994; etc.).

Discussion of Results
Health Beliefs of HIV Patients
Four health beliefs were drawn from the HBM: perceived susceptibility and
severity of the disease, and perceived benefits and barriers of the treatment. The factor
analysis suggested that patients’ perceptions of susceptibility-inaction and susceptibilityaction were different from each other, but related to similarly worded questions about the
risks of non-adherence and benefits of adherence (Table 5-5). This leads to a possible
explanation that the degree to which a patient feels threatened by aggravation of HIV
infection is conditional upon whether or not they take their medications. Perceived
susceptibility may be highly correlated with the perceived effectiveness (i.e., perceived
benefit) of the treatment. For example, a patient who believes that his medications are
highly effective is more likely to believe that he is at lower risk of complications as long
as he takes his medications as prescribed, and that he is at higher risk if he does not take
his medications as prescribed.
The relative severity of the disease was measured by the statement “Compared to
other illness, HIV/AIDS is very serious”.

There was little variability among the

responses of patients as 83.2% of those agreed HIV/AIDS was very serious (Mean =
4.28). This result is comparable to the findings of other compliance studies among HIV
patients (Muma, 1995; Geletko, 1995; Morse, 1991). It illustrates that for a severe
disease like HIV/AIDS, it is difficult and may not be appropriate to measure
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"conditional" perceived severity.
Another finding from the factor analysis on health beliefs was that the perceived
monetary barriers and non-monetary barriers were shown conceptually distinct. This is
consistent with some prior studies on HBM (Ronis, 1992; Nau, 1997). However, many
compliance studies using the HBM construct did not delineate between these two
constructs (e.g., Muma, 1995; Geletko, 1995; Morse, 1991).
Finally, the factor analysis and test of internal consistency showed that the
perceived ability of HIV medications to improve overall health did not fit the scale of
perceived benefits (low factor loading and item-to-total correlation).

Perhaps most

patients feel HIV medications are more effective in stabilizing their disease conditions
than for improving their overall health.
Relationship of Disease Severity and Health Beliefs
There was no relationship between the stage of HIV/AIDS and perceptions of
benefits or barriers of the treatment, or perceived comparative severity of the disease
(Table 5-8). It is reasonable that the actual seriousness of disease did not affect patients’
perceived severity since the majority of patients felt that HIV/AIDS was serious. In
addition, most patients agreed their treatment was very beneficial regardless of their
disease stage. This may be due to the fact that treatments for HIV/AIDS have developed
remarkably in recent years. Compared to treatments in the 1980’s and the early 1990’s,
the new combined antiretroviral therapy has significant improvement in treatment
effectiveness.

The progress is so obvious that most patients appreciate the new

technologies/medicines for prolonging their life and preventing disease aggravation (See
Appendix G: "Patients’ Comments"). It is reasonable that patients’ perceived benefits of
the treatment are quite uniform and not influenced by their actual disease severity.
On the other hand, despite the development in HIV/AIDS medications, side
effects of antiretrovirals are still relatively common and difficult to avoid due to the
limited numbers and classes of antiretrovirals. All antiretroviral agents are associated
with considerable toxicities (Carpenter et al., 1996). Also, the combined antiretroviral
therapy increases regimen complexity, which may be more inconvenient for patients.
Patients without severe disease-related symptoms may perceive high treatment barriers
because the side effects of their medications appear relatively intolerable compared to
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their disease experience whereas patients with advanced disease may perceive high
treatment barriers because they actually experience a greater incidence of adverse effects.
As the course of HIV disease progresses and treatment alternatives become limited, it is
more likely that remaining treatment options will have overlapping adverse effect profiles
(Carpenter et al., 1996). However, patients with AIDS or ARC may also perceive the
side effects of medications and/or other inconveniences caused by the treatment more
tolerable compared to the advancement of their disease. Although the responses to
individual barrier items were mixed, the summated barriers scale indicated that the
overall perception of barriers was relatively high (Table 5-3a).
The means of perceived cost among patients in all three disease stages were
around 3.5 which was above the midpoint, but not very high (Table 5-8). Perceived
monetary cost may be associated with both out-of-pocket price and perceived disease
severity. Therefore, it is understandable that disease severity did not significantly affect
patients' perception of monetary cost since most patients felt HIV/AIDS was a serious
disease and more than seventy percent of the patients have insurance (e.g., Medicaid,
Ryan White Consortium, or other private or state insurance programs) (Table 5-1).
Disease severity was associated with perceived susceptibility-inaction. That
means HIV patients who have had severe complications perceive themselves to be at
greater risk of getting worse when not adherent as compared to patients who have never
experienced complications.

On the contrary, there was no significant difference in

perceived susceptibility-action among HIV patients in different disease stages. This
further verified the conclusion of Ronis (1992) that susceptibility-inaction and
susceptibility-action should be evaluated separately.

The measure of susceptibility-

inaction may be more sensitive to the symptoms patients experienced than that of
susceptibility-action.
Medication Adherence among HIV Patients
Three measures were used in this study to assess medication adherence. Measure1
was developed by Morisky and colleagues (1986). The second and third measures
defined adherence as the percentage of doses taken as prescribed during the past two days
and the past two weeks, respectively. Results showed that these three measures were
poorly compatible with each other (Table 5-4). The agreement between measure2 and
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measure3 was statistically significant (Kappa = 0.3, p < 0.01), but not substantial. No
agreement was shown between measure1 and the other two measures.
Measure1 appeared to be less promising as a measure of adherence when
compared to measure2 and measure3. In contrast to the results of a prior study (Morisky
et al., 1986), measure1 had very low internal consistency ( = 0.39). The item-total
correlations for the four items were also very low (Table 5-7). This indicated that the
measure might not be ideal for this study.
Compared to measure1, measure2 and measure3 are more straightforward.
Although measure3 may be more reflective of the overall trend in the patient's adherence
behaviors, it may be vulnerable to a recall bias.

In addition, measure2 showed more

consistent correlations with the health beliefs examined. Therefore, measure2 (in which
adherence was measured over the past two days) may be more suitable for this study. In
many past studies, adherence was measured by the percentage of doses taken as
prescribed during the past month (Muma, 1995), past week (Samet, 1992, Morse, 1991),
and/or the past 24 hours (Samet, 1992). Using 80% as the adherence cutoff value, the
reported rates of adherence have ranged from 40% to 71% (Tseng, 1998; Samet, 1992;
Remien, 1998).
Inconsistent with the literature, self-reported medication adherence was quite high
in our study patients: 66.2% had perfect adherence during the past two days, 89.7% had
greater than 80% compliance, and only 4.4% missed more than 50% of their doses. The
high adherence rate may be due to a selection bias among patients who didn't participate
in the study. Compared to the patients who were willing to complete the survey and send
it back, non-respondents may have lower adherence, with a resultant overestimation of
compliance (Eraker et al., 1984; Feinstein, 1979; Morse, 1991). Also, it is conceivable
that patients may be more adherent during the two days prior to an appointment. Thus
the adherence rate may not be representative of the general population of persons with
HIV.
Results also revealed that some patients (21.2%) purposefully stopped taking their
HIV medications and the most common reason for intentional non-adherence was the
intolerable side effects of the medication.
Relationship of Disease Severity and Medication Adherence
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Medication adherence increased as patients’ disease severity increased when
regimen complexity was controlled.

The trend was more significant between

asymptomatic patients (stage A) and symptomatic patients (stage B and C) (F = 7.72, p =
0.007). Although one might expect less adherence in patients with more advanced HIV
disease because of their increased medication needs and decreased level of physical
functioning, this is often not the case. Patients who have experienced more disease
symptoms are likely to have higher medication adherence. They may feel a higher risk of
complications or have more experience in coping with the barriers of the treatment (e.g.,
side effects) compared to patients in the early stages of the disease.
Relationship of Health Beliefs, Regimen Complexity and Demographic Factors with
Medication Adherence
Based on the results of a multiple regression analysis, we conclude that patients
are more likely to take their medications as prescribed if they have higher perceived
susceptibility-inaction and/or less difficulty in understanding doctors’ instructions. These
findings are consistent with the literature (Rosenstock, 1966; Ronis, 1992; Tseng, 1998).
However, all other health beliefs were not significantly associated with adherence. Thus,
they may not be the best predictors of medication adherence behaviors of HIV patients.
It is understandable that the perceived severity of the disease (comparative), which the
HBM holds as a predictor of adherence behavior, is not significant in this study due to
uniformly high perceptions of perceived severity.

This supports opinions of Rimer

(1990) and Nau (1997) that the concept of perceived severity in HBM may have low
utility when applied to severe illnesses.
Regimen complexity was found not a significant predictor of medication
adherence. However, many studies have indicated that medication adherence is strongly
associated with regimen complexity (Rudd, 1993; Eraker et al., 1984; Eldred et al, 1997;
etc.). The lack of association in this study may be due to the fact that more than 75% of
the patients took at least five doses a day and there was minimal variation in regimen
complexity. It may also be due to limitations in the measure of regimen complexity. In
this study, regimen complexity was calculated based on the number of daily doses.
Complexity may actually be influenced by other issues such as the timing of the doses.
For example, having to take five medications that are all taken at the same dosing interval
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(e.g., three times a day) may be easier than taking one medication twice daily, along with
another medication dosed three times a day and a third drug dosed four times a day.
Finally, all demographic characteristics of the patients (age, race, gender, income,
education) were not significant predictors of adherence.

Literature regarding the

influence of ethnicity on adherence is inconsistent. A study conducted by Muma et al.
(1995) showed that African-American patients had a lower level of compliance
(independent of education). Some other studies did not find ethnicity associated with
non-adherence (Eldred et al., 1997; Besch et al., 1997; Morse et al., 1991). In this study,
there was no significant difference in medication adherence between white patients and
African-American patients.
Causal Links
Although there is no way to draw a definitive conclusion about the causality
between disease severity, health beliefs (e.g., susceptibility-inaction), and medication
adherence in this study, it is logical that patients' current medication adherence is
influenced by their past disease experiences. It is possible that the effect of disease
severity on medication adherence is mediated by patients' perceived risk of getting worse
given non-adherence (susceptibility-inaction). Greater experience in dealing with disease
symptoms and medication use can lead to a higher perceived risk of complications. The
perceived link between non-adherence and the development of complications may be
reinforced through one's personal or vicarious experience of having developed
complications when non-adherent. Counseling by health professionals on the dangers of
non-adherence may also influence this perception. The extant literature on the Health
Belief Model suggests that a higher perceived susceptibility should translate into
increased adherence behaviors. Conversely, patients who are in better health or who
have had no symptoms may have poor medication adherence because they feel less
immediately susceptible to the complications of the illness (low perceived susceptibilityinaction).

Recommendations for Future Research
This study is one of the first steps in the exploration of the relationship between
disease severity, health beliefs, and medication adherence among HIV patients. It is not
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clear whether the effect of disease severity on medication adherence is mediated by
patients' health beliefs such as perception of susceptibility-inaction. Path-analyses are
needed to verify the theoretical model used in this study.
The relationship of disease severity, susceptibility-inaction, and medication
adherence found in this study should also be tested in other disease states, especially in
some chronic diseases with varied symptoms such as hypertension and heart disease. The
implication of the need to conceptualize and measure conditional perceived disease
severity and susceptibility should also be addressed in these future studies.
Many factors other than disease severity influence patients' health beliefs.
Ethnicity is one of them.

Additionally, ethnicity may affect medication adherence.

Although this study examined the impact of ethnicity on health beliefs and medication
adherence, it is not clear whether the apparent relationship of ethnicity and medication
adherence is caused by site-related factors, patients’ characteristics (e.g., education, drug
use status, etc.), or mediated by patients' health beliefs such as perceived disease severity.
Further research is needed to provide deep insight into the relationship between ethnicity,
health beliefs, and medication adherence.
This study used the number of weekly doses as an indicator of regimen
complexity. In addition, three different measures of medication adherence were used and
compared.

It is hoped that future research will develop more valid and reliable

measurements of regimen complexity and medication adherence.
Finally, non-respondent patients may be more likely to have poor medication
adherence, negative health beliefs, and/or unfavorable socioeconomic conditions. Issues
regarding ways to increase response rate and to target non-respondents need to be
addressed in further research.

Implications of the Study Results
HIV/AIDS is often viewed as a chronic, fatal illness that is managed with multiple
drug therapies. Thus, patients' ability to manage their medications or long-term adherence
to treatment becomes a critical issue. Medication adherence is recognized as an important
factor determining the success of antiretroviral therapy. In order to develop and promote
self-management of disease in HIV patients, partnership between the patient and the
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health care provider is required.
By understanding patients’ medication taking behaviors and addressing
adherence-related issues from patients’ perspectives, health care providers can play an
important role in helping establish optimal adherence in HIV patients. This requires that
health care providers invest time educating patients about their disease and its treatment.
As shown in this study, patients’ medication taking behaviors are influenced by their
disease severity and this influence may be mediated by patients' perceived risk of
developing complications if they fail to adherent to their medication regimen.

The

importance of treatment adherence and the risks of non-adherence should be emphasized
to all patients, especially for asymptomatic patients. Effective counseling should inform
patients that non-adherence may cause disease aggravation and the failure of drug therapy
which will limit future antiretroviral options because of cross-resistance. This is not to
scare patients but to help them understand the potential negative consequences of poor
adherence and encourage them to accept part of the responsibility for their treatment
outcomes.
The results of this study also suggest that difficulty in following physicians’
instructions is a significant barrier of medication adherence. This indicates that patients'
medication adherence can be improved by enhancing the relationship and
communications between patients and health care providers. Patients should always be
encouraged to ask questions and be certain that they understand the instructions about
their medications. It is also important for health care providers to share information
about new therapies, discuss the disease and treatment, and keep patients aware of their
disease. These may seem difficult for clinics with heavy work flow, but they are critical
to decrease medication misuse and non-adherence and effective in reducing revisits in the
long run.
The complexity of drug therapy for persons with HIV/AIDS presents an
opportunity for pharmacists to play a greater role in enhancing drug-related outcomes.
Difficulty in following doctors’ instructions was found to be negatively related to
patients’ medication adherence. Previous studies also revealed that 60% of patients
misunderstood what their physicians told them about medications

(Remien, 1998).

Moreover, patients rarely tell their physicians that they do not understand instructions
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because of time constraints, fearing to appear stupid, or not knowing what questions to
ask (Meichenbaum and Turk, 1987).

Therefore, pharmacists may be able to help

HIV/AIDS patients manage their drug therapy.
This study was carried out in multiple clinic sites, two of which are in rural or
suburban areas and one of which is in a metropolis; thus, the results may be applicable to
patients in both rural and urban settings. However, differences in responses between the
West Virginia and Maryland sites suggest that the characteristics of the site and/or its
patients may be related to health beliefs and adherence. Hence, generalizations regarding
adherence rates and health beliefs should be made cautiously.

Conclusion
The illness experiences of persons with HIV influence how they rate their chances
of developing complications if they are not adherent to their medications. This further
influences their medication adherence behaviors. Patients who have experienced AIDSrelated complications have higher perceptions of their susceptibility to further
complications and have higher medication adherence rates than those earlier in the disease
process.

Difficulties in following doctors’ instructions also affect HIV patients’

medication adherence.

The greater the perceived difficulty in following doctors’

instructions, the lower the medication adherence rate.

Patients' medication taking

behaviors can be improved and the optimal treatment outcomes could be achieved by
targeting issues specific to the individual patient, enhancing the relationship between
patients and health care providers, and helping patients understand the negative
consequences of poor adherence.
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APPENDIX A.

CDC 1993 Revised Classification System for HIV Infection and Expanded AIDS
Surveillance Case Definition System for AIDS Among Adolescents and Adults *

Clinical Categories (See Appendix B)
(A)
Asymptomatic,
acute HIV or PGL

(B)
Symptomatic, not (A)
or (C) conditions

(C)
AIDS-indicator
conditions

(1)  500/L

A1

B1

C1

(2) 200 - 499/L

A2

B2

C2

(3) < 200/L

A3

B3

C3

CD4+ T-cell
Categories

* The shaded cells illustrate the expanded AIDS surveillance case definition.

Source: Centers for Disease Control. 1993 revised classification system for HIV infection and expanded
surveillance case definition for AIDS among adolescents and adults. MMWR 1992; 41 (No.RR-17).
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APPENDIX B.

Clinical Categories Used in CDC 1993 Revised AIDS Surveillance Case Definition

Category A
One or more of the conditions listed below occurring in an adolescent or adult with
documented HIV infection. Conditions listed in categories B and C must not have
occurred.
 Asympotmatic HIV infection
 Persistent generalized lymphadenopathy (PGL)
 Acute (primary) HIV infection with accompanying illness or history of acute HIV
infection

Category B
Symptomatic conditions occurring in an HIV-infected adolescent or adult that are not
included among conditions listed in clinical category C and that meet at least one of the
following criteria: (a) the conditions are attributed to HIV infection or are indicative of a
defect in cell-mediated immunity; or (b) the conditions are considered by physicians to
have a clinical course or to require management that is complicated by HIV infection.
Examples include, but are not limited to:
 Bacillary angiomatosis
 Candidiasis, oropharyngeal (thrush)
 Candidiasis, vulvovaginal; persistent, frequent, or poorly responsive to therapy
 Cervical dysplasia (moderate or severe)/cervical carcinoma in situ
 Constitutional symptoms, such as fever (38.5C) or diarrhea lasting > 1 month
 Hairy leukoplakia, oral
 Herpes zoster (shingles), involving at least two distinct episodes or more than one
dermatom
 Idiopathic thrombocytopenic purpura
 Listeriosis
 Pelvic inflammatory disease, particularly if complicated by rubo-ovarian abscess
 Peripheral neuropathy
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Category C
Any condition listed in the 1987 surveillance case definition for AIDS (or conditions
added in the 1993 revision) and affecting an adolescent or adult. The conditions listed in
category C are strongly associated with severe immunodeficiency, occur frequently in
HIV-infected individuals, and cause serious morbidity or mortality.
Conditions listed in the 1987 AIDS surveillance case definition:
























Candidiasis of bronchi, trachea, or lungs
Candidiasis, esophageal
Coccidioidomycosis, disseminated or extrapulmonary
Cryptococcosis, extrapulmonary
Cryptosporidiosis, chronic intestinal (>1 month duration)
Cytomegalovirus disease (other than liver, spleen, or nodes)
Cytomegalovirus retinitis (with loss of vision)
Encephalopathy, HIV-related
Herpes simplex: chronic ulcer(s) (>1 month duration); or bronchitis, peumonitis, or
esophagitis
Histoplasmosis, disseminated or extrapulmonary
Isosporiasis, chronic intestinal (>1 month duration)
Kaposi’s sarcoma
Lymphoma, Burkitt’s (or equivalent term)
Lymphoma, immunoblastic (or equivalent term)
Lymphoma, primary, of brain
Mycobacterium avium complex or M. kansasii, disseminated or extrapulmonary
Mycobacterium tuberculosis, disseminated or extrapulmonary
Mycobacterium, other species or unidentified species, disseminated or
extrapulmonary
Pneumocystis carinii pneumonia
Progressive multifocal leukoencephalopathy
Salmonella septicemia, recurrent
Toxoplasmosis of brain
Wasting syndrome due to HIV

Conditions added to the AIDS surveillance case definition in the 1993 revision:




Cervical cancer, invasive
Mycobacterium tuberculosis, pulmonary
Pneumonia, recurrent

Source: Centers for Disease Control. 1993 revised classification system for HIV infection and expanded
surveillance case definition for AIDS among adolescents and adults. MMWR 1992; 41 (No.RR-17).
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APPENDIX C.

Indications for the Initiation of Antiretroviral Therapy
in the Chronically HIV-Infected Patient

Clinical Category

CD4+ T-cell Count
and HIV RNA

Recommendation

Any value

Treat

Asymptomatic

CD4+ T-cells < 500/L or
HIV RNA >10,000 (bDNA)
or >20,000 (RT-PCR)

Treatment should be offered. Strength
of recommendation is based on
prognosis for disease-free survival and
willingness of the patient to accept
therapy.

Asymptomatic

CD4+ T-cells > 500/L and
HIV RNA <10,000 (bDNA)
or <20,000 (RT-PCR)

Some experts would delay therapy
and observe; however, some experts
would treat.

Symptomatic (AIDS, thrush,
unexplained fever)

Source: Centers for Disease Control and Prevention. Report of the NIH Panel to Define Principles of Therapy of
HIV Infection. 1997.
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APPENDIX D. Cover Letter

Dear Patient,
Do you or someone you know find it difficult to manage all of your medications?
Would you like to tell us about your experiences with HIV medications? We are
attempting to learn more about how people with HIV view their disease and their
medications. This information could be useful in helping us and other health care
providers understand how people with HIV cope with using multiple medications and
why some people stop using their medications.
We have attached an anonymous questionnaire about your feelings towards HIV
and your medications. If you do not want to complete this survey, you do not have to.
Although we hope that you answer all of the questions, you do not have to answer any
question that makes you uncomfortable. There are no right or wrong answers - just
provide the answers that best match your feelings. The survey should take about ten
minutes to complete.
When you have finished the questionnaire, please seal it in the attached envelope
and return it to us or just drop it in a mail box. The envelope is addressed to our
colleagues at the West Virginia University School of Pharmacy who are helping us
analyze the results of the survey, but since your name is not on the survey they will not
know your identity. Your participation in this survey will not directly affect the care that
you receive, but may help us design more effective treatment plans for persons with HIV.
If you have any questions about this survey, please do not hesitate to ask.
Thank-you,

Xin Gao, B.S.

Doug Drevets, M.D.

R. Wesley Farr, M.D.

Melanie Fisher, M.D.

Gina Marie Foglia, M.D.

Rashida Khakoo, M.D.
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APPENDIX E.

Instructions for the physician:
Step 1. Ensure that patient meets inclusion criteria:





confirmed diagnosis of HIV infection;
using antiretroviral therapy for at least one month;
age 18 years or older;
mentally competent.

Step 2. Please indicate the disease category of the patient as A, B,
or C in the box on the first page of questionnaire according
to the criteria on the following page.
IMPORTANT NOTE ---- The disease category should be
selected based upon whether the patient has EVER
experienced the indicator conditions, rather than his/her
current status.
Step 3. Please give the survey to the patient.

Questions may be directed to Xin Gao (304-293-6991) or Dr.
David Nau (304-293-1453). Thank you.
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APPENDIX F. Questionnarie

Medication Use
Survey
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1. Which of the following medicines have you taken during the past month (check
all that apply)? Please indicate whether you take one of the common doses or take
a different amount of the medication. On the following page, please list any other
medications that you take on a regular basis.
Medication

Common Dose

Other (Please Specify)

Combivir® :
(zidovudine and lamivudine)

___ 1 tablet, 2 times a day

Crixivan® :
(indinavir)

___ 2 capsules, 3 times a day _________________

Epivir® :
(lamivudine, 3TC)

___ 1 tablet, 2 times a day

_________________

 Hivid® :
(zalcitabine, DDC)

___ 1 tablet, 3 times a day

_________________

_________________

Invirase® :
(saquinavir mesylate, SQV)

___ 3 capsules, 3 times a day _________________

 Norvir® :
(ritonavir)

___ 6 capsules, 2 times a day _________________

Rescriptor® :
(delavirdine mesylate)

___ 4 tablets, 3 times a day

 Retrovir® :
(zidovudine, AZT, ZDV)

___ 2 capsules, 3 times a day __________________

 Videx® :
(didanosine, DDI)

Viracept® :
(nelfinavir mesylate)

___ 2 tablets, 2 times a day __________________

__________________

___ 3 tablets, 3 times a day

__________________

Viramune® :
(nevirapine)

___ 1 tablet, 2 times a day

__________________

Zerit® :
(stavudine, d4T) 

___ 1 capsule, 2 times a day

__________________
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Other medications that you take on a regular basis:
Medication

How many doses you take each day

_________________

_____________________________

_________________

_____________________________

_________________

_____________________________

_________________

_____________________________

_________________

_____________________________

2. Has a physician ever told you that you have AIDS?

….…… Yes

No

3. What was your lowest CD4+ count ever?
0 - 99

100 - 199

 200 - 499

 > 500

don’t know

 >500

don’t know

4. What is your most recent CD4+ count?
0 - 99

100 - 199

 200 - 499

5. What was your highest viral load ever?


<20,000

 20,000 - 750,000

 >750,000

don’t know

 >750,000

don’t know

6. What is your most recent viral load?


<20,000

 20,000 - 750,000

7. How often do you visit or contact your physician?
More than once a month
Once a month
Once every 2 - 3 months
Once every 4 - 5 months
Once every half a year or longer
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8. How long have you been taking medications for HIV/AIDS?
0 - 1 month
2 - 3 months

 4 - 6 months
More than 6 months

9. How do you pay for your HIV medications? (Check all that apply)
 Medicaid
Drug Company

Private Insurance
 Self-Pay

Ryan White Consortium
Other _________

10. If you do NOT take your HIV medications as directed, how would you rate the
chances of your disease getting worse ( i.e. develop AIDS-related complications)?
 Very Low

Low

Intermediate

 High

 Very High

11. If you take your HIV medications as directed, how would you rate the chances of
your disease getting worse ( i.e. develop AIDS-related complications)?
 Very Low

Low

Intermediate

 High

 Very High

Please indicate to what extent you agree or disagree with the following statements.
Strongly Disagree Neutral Agree Strongly
disagree
agree

12. Compared to other illnesses, HIV/AIDS
is NOT very serious. …. .... .... .... .... … 









13. If I do NOT take my HIV medications as
prescribed, I will become very sick. ….











14. If I take my HIV medications as
prescribed, I will still become very sick.











15. Taking HIV medications as prescribed
can prolong my life. …. …. .... .... .... ...
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Strongly Disagree Neutral Agree Strongly
disagree
agree

16. Taking HIV medications interferes a
great deal with my normal activities. … 









17. The HIV medications that I’m taking are
too expensive for me. …. …. …. …. …. 









18. Taking HIV medications exactly as
prescribed decreases the chances of
my illness getting worse. …. …. ….











19. HIV medications cause annoying
side effects. …. …. …. …. ….











20. Taking HIV medications or having side
effects from them has made me feel
more nervous or depressed than usual.











21. Dealing with the side effects of
HIV medications is stressful. …. ….











22. The HIV medications that I’m taking will
improve my health ( i.e. raise immune
system, cause weight gain, etc.). ….











23. HIV medications will work more
effectively if I take them only when I am
feeling bad. …. …. …. …. …. …. ….











24. It is difficult to follow doctors’
instructions on HIV medications. …. ….











25. Taking my HIV medications is
worth the hassle. . …. ….. …. …. ….











26. Overall, would you say your experiences with HIV medications have been:
Negative

Somewhat Negative Neutral

105

Somewhat Positive

Positive

27. Do you ever forget to take any of your medications? …… Yes

No

28. Are you always careful about taking your medications? … Yes

No

29. When you feel better do you sometimes stop taking your
medication? ………………………………………….………. Yes

No

30. Sometimes if you feel worse when you take the medication,
do you stop taking it ? ……………………………………… Yes

No

31. Over the past two days, how many doses of your HIV medications have you
missed? ____________
32. Over the past two weeks, how many doses of your HIV medications have
you missed? ____________

33. Have you purposefully chosen to discontinue any of your HIV medications?
Yes

No

If Yes, what medication(s) did you discontinue? _______________________
Why did you discontinue these medications (check all that apply)?
their side effects are intolerable.
they are nothelpful.
 they are expensive.
 taking them is complicated and inconvenient for me.
 refilling prescriptions or regular clinic check is a burden on me.
 I heard/observed worsening of HIV symptoms in others taking their medications.
 I heard/observed positive results in others not taking their medications.
I want to reserve them for when I am feeling worse.
Other Reasons: Please tell us as much as you can in the space below.

PLEASE GO TO THE NEXT PAGE.
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A. Age:

18-24

25-34

B. Gender:

 Male

 Female

35-44

45 or older

C. Ethnic Origin:
White
Hispanic

Black or African-American
Asian or Pacific Islander

American Indian
Other

D. What is the highest level of education that you have completed?
Less than 9th grade
Some college, no degree
Graduate or professional degree

9th to 12th grade
Bachelors degree

E. What was your approximate household income before taxes, in 1997?
less than 10,000
 10,000 - 19,999
 20,000 - 29,999
 30,000 - 49,999
 50,000 or more
If you would like to tell us anything else about medications for HIV, please write
them below.
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Thank You for taking time to complete this survey. Your
responses are very important and we truly appreciate your
effort and cooperation. Please return the questionnaire in
the self-addressed envelope. No postage is required.
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APPENDIX G.

Patients' Comments
1. I feel guilty and stressed for not taking my medications as prescribed. But when I
take them as prescribed, I feel bad. So, I take them once a day. This makes me feel
evil, ungrateful, bad, etc.
2. Triple therapy is by far the best option so far. If we can find a way to stop diarrhea,
(that will be) great.
3. I know taking HIV medication as prescribed can prolong my life.
4. They are too expensive, it is hell dealing with my HMO.
5. Viracept needs some sort of coating: taste disgusting since it dissolves immediately.
6. Side effects are horrible! Adherence can be very difficult due to a variety of
circumstances. However, I feel it's worth taking the medications because I feel they
definitely prolonged my life.
7. Having the doctors who are easy to communicate with makes taking medications
much easier. Pharmacists also play a key role in this communication process.
8. People should take the medications because it does help and all you have to do is
think positive and other people should help as think positive about the medications.
Thank you.
9. I reduced the dosage so that my supply would last longer as I don't have the money to
afford all three antiretrovirals in my regimens. (Also) I discontinued DDI/DDC
because of side effects manifested by severe pain in liver.
10. Some of my answers regarding tolerance and/or compliance were specific to another
period of time in my life - I've been on AZT for 8 years. Therefore the answers may
not reflect my current tolerance/compliance. But all in all, I'm grateful to have the
medications/care that I get - I'm thankful for each day and every thing I have. People
in this country have no idea how good they have it.
11. If it wasn't for them, I don’t think any of us infected would be alive with out the
blessing of God! Thank You!!
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12. I very seldom miss a dose but often find myself taking them an hour or two earlier or
later than scheduled.
13. Less pills to take at one time could make it more easy to carry with you.
14. I’m still experiencing a very low appetite, very sore knee and elbow joints. Very
difficult scheduling medication around meals. I hardly miss my doses of medication
now by taking of 3 crixivan twice a day instead of 2 three times a day.
15. I feel very ill from the side effects more so than ever in my life. I feel weak. My
muscles, legs and shoulders hurts. I am always nauseated. I feel sick at my stomach.
The diarrhea stays more than goes away. I get terrible headaches. The sun makes me
break out in a rash I get very sick if I get too hot. My muscles twitch in my arms and
legs. This is new. I drink a lot of water but my back (kidneys) hurt sometimes. I drink
more water. My urine looks like oil in the water at times and smells real strong of the
medications. But I'm very careful about my medications and never miss one dose.. I
am committed.
16. With this drug cocktail I became very ill: lost weight and became hospitalized. It was
a bad experience for me. The medications that I am taking right now have been
wonderful. I have my health back along with my life. If it weren’t for my doctors:
Dr. hernandez, Dr. Szego and my pharmacist Christine Teague, I wouldn’t be here.
17. Thanks God for the treatment I get.
18. If you were prescribe by your doctor to take medicine you should take it for a longer
life and feel better.
19. Patient says "taking my medicines makes me feel like I have a chance to live longer.”
20. I don't believe any HIV medications are ultimately life-saving: they prolong rather
than eliminate the risks of end-stage. So I comply with treatment with great hope or
faith in their efficacy. Yes, the regiments are a hassle, but when I think of all the
people in the Third World who die their lack of access to any of these medications I
keep my complaints to my myself.
21. I think the medications work and has done a good deed for me. More people need to
know about it. It is like getting a second chance of life.
22. To me, my medications were a blessing to me. Thank you.
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